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Resumo 
 
 
 
De acordo com dados disponibilizados pela Organização Mundial 
de Saúde, cerca de 8,2 milhões de pessoas morrem anualmente 
com cancro. A elevada taxa de mortalidade associada ao cancro 
resulta da maioria dos pacientes não efetuar exames de rotina e 
porque a manifestação dos sintomas, na maioria dos casos, 
acontece quando o paciente já se encontra numa fase avançada 
da doença. Atualmente, o cancro da próstata representa a segunda 
maior causa de morte entre indivíduos do sexo masculino em todo 
o mundo. Tendo em conta que não existe cura para casos 
avançados de cancro da próstata, a estratégia passa por um 
diagnóstico precoce que permita aumentar a taxa de sucesso dos 
tratamentos. O antigénio prostático específico (PSA) é um 
biomarcador importante do cancro da próstata que pode ser 
detetado em fluidos biológicos, nomeadamente sangue, urina e 
sémen. No entanto, os kits comerciais disponíveis utilizam 
amostras de sangue e os métodos analíticos normalmente 
utilizados na sua deteção e quantificação requerem pessoal 
especializado, equipamento específico e um processamento 
extensivo das amostras, resultando em processos com um elevado 
custo associado. Assim, o objetivo deste mestrado passou por 
desenvolver um método simples, eficiente e menos dispendioso 
para a extração e concentração de PSA a partir de amostras de 
urina utilizando sistemas aquosos bifásicos (SAB) constituídos por 
líquidos iónicos.  
Numa fase inicial, determinaram-se os diagramas de fases de um 
conjunto de sistemas aquosos bifásicos constituídos por um sal 
orgânico e por líquidos iónicos. Em seguida, avaliou-se a 
capacidade dos mesmos para a extração do PSA. Os resultados 
obtidos demonstram que, nos sistemas em estudo, o antigénio 
prostático específico é totalmente extraído para a fase rica em 
líquido iónico num único passo. Por fim, averiguou-se a 
aplicabilidade dos SAB estudados para a concentração do PSA a 
partir de soluções aquosas e de urina. A baixa concentração deste 
biomarcador na urina (clinicamente significativo abaixo de 150 
ng/mL) dificulta a sua deteção através de técnicas analíticas 
convencionais. Os resultados obtidos demonstraram que é 
possível extrair e concentrar PSA até 250 vezes, numa única 
etapa, sendo este detetável através de técnicas menos 
dispendiosas. 
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abstract 
 
According to the World Health Organization, around 8.2 million 
people die each year with cancer. Most patients do not perform 
routine diagnoses and the symptoms, in most situations, occur 
when the patient is already at an advanced stage of the disease, 
consequently resulting in a high cancer mortality. Currently, 
prostate cancer is the second leading cause of death among males 
worldwide. In Portugal, this is the most diagnosed type of cancer 
and the third that causes more deaths. Taking into account that 
there is no cure for advanced stages of prostate cancer, the main 
strategy comprises an early diagnosis to increase the successful 
rate of the treatment. The prostate specific antigen (PSA) is an 
important biomarker of prostate cancer that can be detected in 
biological fluids, including blood, urine and semen. However, the 
commercial kits available are addressed for blood samples and the 
commonly used analytical methods for their detection and 
quantification requires specialized staff, specific equipment and 
extensive sample processing, resulting in an expensive process. 
Thus, the aim of this MSc thesis consisted on the development of 
a simple, efficient and less expensive method for the extraction and 
concentration of PSA from urine samples using aqueous biphasic 
systems (ABS) composed of ionic liquids. 
Initially, the phase diagrams of a set of aqueous biphasic systems 
composed of an organic salt and ionic liquids were determined. 
Then, their ability to extract PSA was ascertained. The obtained 
results reveal that in the tested systems the prostate specific 
antigen is completely extracted to the ionic-liquid-rich phase in a 
single step. Subsequently, the applicability of the investigated ABS 
for the concentration of PSA was addressed, either from aqueous 
solutions or urine samples. The low concentration of this biomarker 
in urine (clinically significant below 150 ng/mL) usually hinders its 
detection by conventional analytical techniques. The obtained 
results showed that it is possible to extract and concentrate PSA, 
up to 250 times in a single-step, so that it can be identified and 
quantified using less expensive techniques. 
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1.1. Scopes and objectives 
Prostate cancer is the second more common type of cancer, and represents 15% of 
the cancer-related diseases in males (1). Despite the efforts in the search of new and 
effective therapies, up to now, none of the known therapies is entirely effective when the 
diagnosis is carried out at an advanced stage, emphasizing thus the importance of early 
detection as a powerful way to increase the curative successful rate (2). Prostate cancer is 
usually identified through biopsy, a procedure that is still known as the diagnostic “gold 
strand”. However, associated with this procedure, there are several and serious side 
effects, like febrile urinary tract infection (UTI), urosepsis, bleeding and hematuria. In 
addition, this procedure is also connected to 15%-20% of false negative results (3). 
Therefore, it is of crucial importance to find non-invasive diagnostic tools that could 
replace the commonly used biopsy. The identification and quantification of cancer 
biomarkers in human serum and urine is a potential alternative and has received a 
significant attention in the past few years (4). For instance, the identification and 
quantification of the prostate specific antigen (PSA) is the most widely used assay to 
detect prostate cancer at earlier stages bypassing unnecessary biopsies and reducing the 
number of patients where metastatic disease is found (5). 
 Currently, there are diverse companies (6) that offer several commercial kits for 
the PSA quantification in blood samples, but some of them require the use of 
immunoassay-qualified antibodies, specific and expensive equipment and highly skilled 
technical operators – time-consuming and expensive immunoassays (7,8). Thus, the main 
objective of this work comprises the development of an alternative technique for the 
extraction and concentration of PSA from human urine using a liquid-liquid extraction 
procedure. This procedure should allow the concentration of PSA up to levels capable of 
being detected by more accessible and less expensive equipment, such as high-
performance liquid chromatography (HPLC). To achieve this goal, aqueous biphasic 
systems (ABS) composed of water, ionic liquids (ILs) and organic salts were investigated. 
In the past decade, a large effort has been dedicated to IL-based ABS since these systems 
have demonstrated superior extraction efficiencies and selectivities when compared to the 
more traditional polymer-based ABS (9). Moreover, moderately toxic imidazolium-based 
ILs with no buffering capacity have been the most studied class of phase-forming 
components of IL-based ABS (10). The control of the pH of the aqueous medium is highly 
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relevant when working with the extraction and concentration of proteins (such as PSA) 
since they can denaturate and precipitate, leading therefore to non-accurate results. To 
overcome these drawbacks, ILs comprising anions derived from Good’s buffers, which 
have shown to have self-buffering characteristics (11), in combination with biodegradable 
organic salts, were investigated in this work. 
 This work starts with a brief statistical analysis on the cancer incidence and 
mortality, followed by a small introduction to carcinogenesis, where the role of mutations, 
tumor suppressor genes and oncogenes are highlighted with special emphasis on prostate 
cancer (CaP). The molecular characteristics of PSA (a prostate cancer biomarker) and its 
derivatives are then presented and reviewed. Further, the common methods for PSA 
quantification from human fluids, and IL-based ABS as a liquid-liquid extraction 
technique, are introduced and described. Finally, this work ends with the experimental 
results achieved using IL-based ABS for the extraction and concentration of PSA from 
human urine samples and respective discussion. Outstanding complete extractions and 
concentration factors up to 250-fold were obtained in a single-step, allowing thus the use 
of HPLC as a less expensive technique for the quantification of PSA levels in human 
fluids. 
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1.2. Cancer update overview  
 1.2.1. Epidemiology 
Cancer is the major death cause in the world with an estimated 14.1 million new 
cases and 8.2 million deaths in 2012 and, according to projections for 2030, the number 
of new cases will increase 68% (up to 23.6 million) (12). More than 80 billion € are spent 
each year in USA to deal with cancer healthcare (13). Therefore, more investment in 
cancer early detection assays and in new therapies in order to increase the lifespan of 
patients, as well as to decrease medical costs of advanced cases of disease, are urgent 
requirements. Lung, female breast, bowel and prostate cancers are the most common solid 
neoplasms (Fig. 1.1.). Portugal has a rate of 246.21 per 100,000 individuals which means 
an incidence of 49,174 cancer new cases per year, resulting in an overall number of  
25,758 deaths in 2012 (14). 
 
Figure 1.1. Bars-plot of new cancer cases and deaths of worldwide population in 2012 (numbers 
in millions of new cancer cases/deaths) (12). 
 
 Prostate cancer (CaP) is the second most common diagnosed cancer in males with 
more than 1.11 million new cases worldwide and almost 40% of them – 417,000 – were 
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diagnosed in Europe, meaning that the CaP incidence is not equally distributed around 
the world (1). However, CaP mortality is equally distributed around the world (15).Thus, 
cancer incidence is not equally distributed but mortality is. In Portugal, for instance, CaP 
is the third most common cancer-related cause of death (1582 deaths) and the most 
diagnosed cancer (6622 cases). The number of new cases has been increasing in the past 
few years and there are some alarming reports that predict a rise of more than 30% in new 
CaP cases to 2030 (Fig. 1.2.) (1,14). 
 
Figure 1.2. Number of new cancer cases in Portuguese population (males) in 2012 (dark-blue), 
and predictions to 2015 (blue) and 2030 (light-blue). Numbers for the 5 most common types of 
cancer in Portugal (13). 
 
1.2.2. Carcinogenesis: molecular changes and risk factors 
Cancer is the word used to describe a group of diseases in which abnormal cells 
tend to divide. In this multistep process, cells can suffer severe behavioral and metabolic 
alterations and ultimately invade distant tissues and form metastases via blood and 
lymphatic systems (16). Cancer types can be divided into 5 categories according to their 
source (Table 1.1.). These include carcinoma, sarcoma, leukemia, lymphoma, myeloma 
and central nervous system cancers. 
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Table 1.1. Categories of cancer types according to their source ((17)15). 
Cancer type Source 
 
 
Carcinoma 
 
Cancer begins in the skin or in tissues around internal organs. 
Carcinoma is subdivided into adenocarcinoma (starts in 
glandular cells), basal cell carcinoma (begins in the lower part of 
the epidermis), squamous cell carcinoma (begins in squamous 
cells) and transitional cell carcinoma (occurs mainly in the 
organs of the urinary system). 
Sarcoma Cancer begins in connective or supportive tissues, like cartilage, 
fat, bone and blood vessels. 
Leukemia Bone barrow produces a large number of abnormal blood cells that 
enter into the bloodstream. 
Lymphoma  Develops in glands or nodes of the lymphatic system. Lymphomas 
are classified into Hodgkin lymphoma and non-Hodgkin 
lymphoma. 
Myeloma Cancer that originates in plasma cells of the bone marrow. The 
plasma cells produce some of the proteins found in blood. 
Mixed types The type components may be within one category or from different 
categories, such as adenosquasmous carcinoma, mixed 
mesodermal tumor and teratocarcinoma. 
 
The process by which cells lead to cancer is called carcinogenesis and is a 
multifactorial process that involves 3 major steps (18). The first step comprises the 
initiation, in which due to genotypical and phenotypical changes that arise spontaneously 
or are induced by exposure to a carcinogen, normal cells become more likely to malign 
evolution. A cell that suffers such changes is called an initiated cell and suffers mutations 
that induce proliferation but not differentiation. Thereby, the proliferating initiated cells 
have less time to be repaired by the DNA repair system and the injury becomes permanent 
and irreversible; so, the cellular genome undergoes mutations that favor the neoplastic 
development of the affected cells (19). The cellular genes involved in this step are the 
proto-oncogenes. They are groups of genes that when mutated cause normal cells to 
become cancerous. However, they are not discarded by evolutionary processes because 
they have important roles, such as the encoding of proteins that stimulate cellular division, 
inhibition of cellular differentiation and are involved in signal transduction. Proto-
oncogenes have, as usual in all other genes, a regulatory region that regulates the gene 
expression, and a structural region that encodes the amino acid sequence of a protein. 
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Mutations in any of these regions can activate a proto-oncogene, creating an oncogene 
(20). There are several types of known oncogenes, such as RAS, MYC, ERK, TRK or 
WNT. Another oncogene type is the Bcr-Abl gene, found on the Philadelphia 
chromosome (21). This oncogene is a known example of an oncogenic chromosomal 
translocation wherein a piece of chromosome 22 end with the BCR geneis broken, and 
then suffers fusion with a fragment of chromosome 9 that carries the ABL-1 gene, 
yielding thus the Philadelphia chromosome with the BCR-ABL fused gene. This 
oncogene is translated into tyrosine kinase receptors that are involved in cell cycle 
regulation and stimulation of cell division, leading to uncontrolled cell division which 
can cause chronic myelogenous leukemia (CML) and other types of leukemia (21). 
The second step of carcinogenesis is promotion. After initiation, a cell can remain 
latent for weeks, months or years until and unless it is stimulated to undergo further 
proliferation, disturbing the cellular balance. Promoter compounds act at this stage only 
in the activated cells, inducing cell proliferation of susceptible tissues, helping to fix 
mutations, increasing alterations in genetic expression and causing changes in cellular 
growth control. This causes the onset of new oncogenes and disruption of the tumor 
suppressor genes action, leading to neoplastic transformation and development (22,23). 
Tumor Suppressor (TS) genes are a group of genes that regulate cell proliferation by 
checking the cell cycle progression, are involved in DNA repair processes preventing the 
accumulation of mutations in cancer-related genes and stimulate cell death when an injury 
is detected, and so, they are known as negative growth regulators (24). One of the most 
studied TS genes is p53, which is a protein encoded by the TP53 gene and has an 
important role in cellular and genomic equilibrium – reason for “The guardian of the 
genome” label. Mutations in this gene were found in at least 50% of human cancers. This 
TS gene regulates the cells cycle in the G1-S checkpoint, induces cell differentiation and 
promotes apoptosis. In a normal cell, when DNA damage is detected, p53 binds to DNA 
and stops the cell cycle. This happens because p21, a protein whose transcription is 
activated by p53, binds to cdk-cyclin complex inhibiting its kinase activity which causes 
a delay in G1 checkpoint and enabling the DNA repair mechanisms to act. If DNA is 
repaired, p53 promotes its differentiation and multiplication. If the cell cannot be repaired, 
p53 gives information to be eliminated by apoptotic processes. Therefore, when p53 is 
mutated, it can lose its function causing suppression of apoptosis, promoting cell division 
and hindering the differentiation of the cells. There are another important types of TS 
genes, like RB1, APC, BRCA1/2, among others (25).  
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The last step in carcinogenesis is the progression, a step where pre-neoplastic 
lesions and/or benign neoplasms turn into malign lesions. Progression is characterized by 
irreversibility, because once in this condition, cells are compromised into the malign 
development. The acquired genetic instability causes undifferentiated cells to proliferate 
faster while the well differentiated and slow growth cells die. There are also some 
biochemical, metabolic and morphological changes, as well as the appearance of new cell 
clones with genetic heterogeneity with a high capacity to proliferate and metastasize, 
which will induce the formation of a tumor mass (26,27).  
There are few theories regarding the explanation of how cancer starts and what 
causes its development; the most widely accepted is the “two hit” hypothesis, based on 
the mechanisms of retinoblastoma, proposed by Alfred Knudson in 1971 (28). In an initial 
stage of retinal cancer, retinoblasts do not differentiate into retinal photoreceptors cells 
and nerve cells, and continue to proliferate forming tumors in retina able to metastasize 
to other parts of the body. Knudson (28) studied 48 patients with retinoblastoma for 20 
years, and tabulated the patient age, family history, gender, and if the tumor occurs in one 
or in both eyes. With the obtained data and knowing that retinoblastoma is caused by a 
recessive mutation, the researcher verified that bilateral hereditary retinoblastoma 
occurred at a younger age while unilateral nonhereditary retinoblastoma is somehow 
delayed (28). Based on these findings, the researcher concluded that two mutations or 
“two hits” are required, one in each copy of a TS gene (today called RB1) (28). In 
hereditary cases, patients get one mutation and need to acquire only one to develop 
retinoblastoma in a process known as loss of heterozygosity. In what concerns to non-
hereditary cases, patients have to acquire 2 mutations during their life to develop this type 
of cancer, what explains why nonhereditary retinoblastoma is developed latter. This is 
one of the most accepted theories for cancer-related researches; however, it is not 100% 
correct because it only takes into account mutations in TS genes (28,29). 
Family history seems to be one of the most important factors which can lead to 
cancer (28). In general, 5-10% of all cancers are hereditary (30). One of the most common 
syndromes is the hereditary non-polyposis colorectal cancer (HNPCC) or Lynch 
syndrome. This syndrome is mostly related with endometrial cancer but it is also 
associated with ovary, stomach, pancreas, kidney and brain cancers. In HNPCC, genes 
involved in the DNA repair mechanism are mutated leading to cancer development (31).  
Aging is another predisposing factor in carcinogenesis. During aging, DNA 
strand-break occurs in tissues and there is the accumulation of DNA adducts, assumed to 
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be caused by an imbalance between cellular pro-oxidants and antioxidants. In cellular 
metabolic processes, free radicals and reactive species of oxygen (ROS) are produced. 
These cellular antioxidants are accumulated over the years and damage macromolecules 
and organelle functions due to their high reactivity (32). Inflammation is also an important 
factor in oncogenesis. With aging, cellular damage increases, and in order to fix this 
damage, cells tend to produce cytokines, such as the tumor necrosis factor (TNF)-α, 
interleukin (IL)-1, IL-6,interferon (IF)-γ and  C-reactive protein (CRP), resulting in a state 
known as low-grade chronical inflammation. The rising in cytokines concentration affect 
angiogenesis what may enhance cell proliferation (33). Finally, epigenetic alterations are 
also connected to cancer. These are genome modifications during cell division that do not 
involve changes in the DNA sequence, have a hereditary character, are able to modify 
gene expression and affect all tissues and cells throughout life (34). DNA methylation at 
CpG islands is a common epigenetic alteration. CpG islands are short regions of 0.5-4 kb 
in length rich in CpG and are located in promoter regions of half the genes in mammalian 
genome, including TS genes (35). Usually, they are un-methylated; yet, in cancer, 
hipermethylation occurs blocking the action of  the genes involved in cells cycle 
regulation, resulting in their uncontrollable proliferation and cancer development (36). 
Histone modifications, such as ubiquitylation, methylation, acetylation and 
phosphorylation are other epigenetic alterations more usual with aging. They affect the 
chromatin structure leading to deregulated expression of important genes in cancer 
progression (34). 
The human’s diet also affects the probability of cancer development. Some studies 
indicated that a longer and planed low-fat dietary pattern can decrease the probability of 
developing cancer (37,38). A fiber-rich diet is also associated with a lower risk of colon 
cancer (39). Excessive consumption of alcohol has been proved to be associated with the 
development of head, neck, esophageal, liver, breast and colorectal cancers. For instance, 
ethanol in alcoholic drinks is metabolized to acetaldehyde that damages genetic material 
and proteins (40). There are still some carcinogenic compounds added to food or 
produced during its preparation. One of them is acrylamide, present in foods heated above 
120  ºC, such as potato chips, and that was found to have a positive association with renal 
cancer (41). Heterocyclic amines (HCs) and polycyclic aromatic hydrocarbons (PAHs), 
produced when amino acids, sugars and creatinine of the meat are directly exposed to 
fire, particularly when they are grilled or barbecued, were also found to be mutagenic 
(43). Moreover, pesticides used in food products can persist in environment and 
 11 
 
bioaccumulate in the body, and thus be responsible for some type of cancer, and in 
particular of pancreatic and breast cancers (42). 
People lifestyle is another important factor in the probability of developing cancer. 
Overexposure to UV sunlight radiations leads to gene mutations, oxidative stress and 
inflammatory responses. In addition, UV radiations cause direct mutations in the TS gene 
p53, and are responsible for cancers like melanoma and basal cell carcinoma (44). 
Cigarette smoke, either as active or as a passive smoker, is also a carcinogenic inductor. 
More than 7000 chemicals are found in cigarretes and at least 69 of them were identified 
as carcinogenic, including nitrosamines, radioactive elements and PAHs, and whose 
action is responsible for the oral, esophageal, lung and pancreatic cancers (45). In 
summary,  a balanced diet combined with frequent physical activities are fundamental in 
cancer prevention, particularly for breast, endometrial and colon cancers (46). 
Viral infections caused by Helicobacter pylori and Human papillomaviruses can 
also promote carcinogenesis. Helicobacter pylori is a food and water contaminant capable 
of suppressing immune responses and causing gastric cancer (47). Human 
papillomaviruses are a group of sexually transmitted viruses responsible for the largest 
majority of cervical, vulvar and vaginal cancers (48). 
1.3. Cancer biomarkers 
One of the most revolutionary advances in oncologic diagnoses and related 
therapies was the detection and role of cancer biomarkers. According to the National 
Cancer Institute, a biomarker is a “biological molecule found in blood, other body fluids 
or tissues that is a sign of a normal or abnormal process, or of a condition or disease” and 
“may be to see how well the body responds to a treatment for a disease or condition” (49). 
Biomarkers can be produced by cancer cells or produced by the human body in response 
to cancer (Table 1.2.). Usually, most biomarkers are proteins but, more recently, 
additional biomarkers such as DNA, metabolites or RNA transcripts have been identified 
(4). 
The “ideal” tumorous biomarker does not exist. In fact, it is difficult to find a 
100% reliable biomarker especially in early detection and diagnosis. Their lack of 
specificity, and the fact that some markers are normally produced by the body and their 
action as cancer biomarkers is associated to concentration levels in body fluids, leads to 
some controversy in what regards the cut-off values established for biomarkers as an 
indication of cancer (50). Thus, an ideal biomarker, should be easy to identify in recurrent 
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screenings, should be able to diagnosis cancer in an early-stage, and should allow the 
evaluation of the prognosis status. Moreover, their identification and quantification 
should be consistent and accurate, and by non-invasive, cheap, and easily accessible 
methods (4,51). In general, the PSA quantification by blood tests is still the most reliable 
screening of prostate cancer (5).
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Table 1.2. Cancer biomarkers identified in biological fluids or tissues in cancer diagnosis, stage, response to treatment and prognosis (51). 
 
Tumorous biomarker Biological fluids or tissues Cancer type Utility 
Alpha-Fetoprotein (AFP) Blood Liver, germ cells tumors 
Liver cancer diagnosis and 
response to treatment; 
Stage, prognosis and response 
of germ cell tumors. 
Beta-2-microglobulina (B2M) 
Blood, urine or 
cerebrospinal fluid 
Multiple myeloma, chronic 
lymphocytic leukemia 
Prognosis and to follow the 
individual response to 
treatment. 
Beta-human chorionic gonadotrofin 
(Beta-hCG) 
Urine or blood 
Choriocarcinoma, testicular 
cancer 
Identification of stage, 
prognosis, and response to 
treatment. 
BCR-ABL fusion gene Blood and/or bone marrow Chronic myeloid leukemia 
Diagnosis and to monitor the 
disease status. 
Bladder tumor antigen (BTA) Urine Bladder 
Confirm diagnosis; used with 
NMP22 to test cancer. 
recurrence. 
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CA15-3/CA27.29 Blood Breast cancer 
To assess therapy results and 
disease recurrence. 
CA19-9 Blood 
Pancreas, gallbladder, bille 
duct, stomach 
To assess therapy results. 
CA-125 Blood Ovaries 
Diagnosis, assessment of 
response to treatment, and 
evaluation of recurrence. 
Calcitonin Blood Medullary thyroid  
Diagnosis, assessment of 
response to treatment, and 
evaluation of recurrence. 
Carcinoembryonic antigen (CEA) Blood 
Colorectal cancer and breast 
cancer 
To check if cancer has spread; 
Assessment of response to 
treatment and evaluation of 
recurrence. 
CD20 Blood Non-Hodgkin lymphoma  
To check if a targeted therapy 
is appropriate. 
Chromogranin A (CgA) Blood Neuroendocrine tumors  
Diagnosis, assessment of 
response to treatment, and 
evaluation of recurrence. 
Cytokeratin fragments 21-1 Blood Lung Evaluation of recurrence. 
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Immunoglobulins 
 
Blood and urine 
 
Multiple myeloma 
and Waldenström 
macroglobulinemia 
 
Diagnosis, assessment of 
response to treatment, and 
evaluation of recurrence. 
Lactate dehydrogenase  Blood Germ cell tumors 
To assess the cancer stage, 
prognosis, and response to 
treatment. 
Prostate-specific antigen (PSA) Blood and urine Prostate 
Diagnosis, assessment of 
response to treatment, and 
evaluation of recurrence. 
Prostatic acid phosphatase (PAP) Blood 
Prostate, lung, multiple 
myeloma 
Diagnosis. 
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1.4. Prostate cancer 
1.4.1. Etiology 
Prostate cancer (CaP) is one of the most common males’ cancers in the world (1). 
The vast majority of prostatic tumors are adenocarcinomas with origin in prostatic 
epithelium. CaP is a multifactorial disease, where there is a relation between aging and 
environmental, physiological and molecular factors. Advanced age and its associated 
oxidative stress, low grade-chronical inflammation and epigenetic alterations are the most 
significant risk factors with an important role in tumor initiation (52). Around 60% of 
tumors are diagnosed in men with more than 65 years old, and 97% in men with more 
than 50 years old (1). Exposure to UV radiation, diet, alcohol consumption, family 
history, ethnicity and hormones are additional factors involved in the development of 
CaP. African or American men with more than 65 years and with a first-line familiar who 
had this type of cancer are those with a higher risk in CaP development (52).  
In what concerns the molecular changes, some important mechanisms should be 
highlighted. The Wnt signaling pathway is a major signaling pathway involved in 
invasiveness of prostate tumor cells. Her-2/neu (ERBB2) is a proto-oncogene involved 
in, among others, prostate cancer. When active it is important in the differentiation and 
cells growth of tumor wherein high levels of Her-2/neu are related with metastatic 
prostate cancer. Phosohoinositide-3 Kinase/AKT (PI3K) is a mediator of several 
oncogenic signaling pathways and it is activated by receptor tyrosine kinases yielding 
secondary messengers promoters of cellular proliferation and survival. Due to somatic 
mutations, PI3K can be hyperactivated promoting the prostate cancer progression (53). 
Nowadays, there are no effective therapies for CaP if the tumor already spread the limits 
of the organ. Therefore, efforts and investments in the CaP early detection are critical 
requirements to increase the curative successful rate (14). 
1.4.2. Signals, symptoms and diagnosis 
Prostate cancer, as many other cancer types, can be effectively treated with 
surgery and radiation if detected at an early stage. However, a relevant percentage of 
patients is only diagnosed after demonstrating symptoms like haematuria, urinary 
obstruction, polyuria, among others. In more severe cases, when the tumor reaches the 
lymph nodes or bones, oedema and pain are major symptoms (54). At this stage, the 
treatments typically used are no longer efficient and the 5-year relative survival rate 
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decreases (2). This fact puts on evidence the screening importance attempting an early 
detection of CaP and the need to perform diagnostic tests even in the absence of signals 
and symptoms of the disease, which is in fact the biggest challenge in CaP diagnosis.  
Digital rectal examination (DRE), measurement of the serum total PSA and 
transrectal ultrasound (TRUS) guided biopsies are the usual methods to detect CaP. If 
DRE and PSA as initial tests indicate the presence of the disease, TRUS guided biopsy is 
further carried out to confirm the diagnosis. Despite being widely used, these tests display 
however some disadvantages. The PSA cut-off test is not consensual because a serum 
PSA concentration above the threshold limit is not necessarily a result of CaP. Recent 
ejaculations, benign prostate hyperplasia (BPH) and urinary or prostatic infections can 
also increase PSA concentration. So, in the case of such over-diagnostics, unnecessary 
treatments, including prostatectomy and radiation therapy, will be conducted. DRE is a 
qualitative test and it is not possible to reach/evaluate the entire prostatic gland, especially 
in small tumors that have not reached yet the prostatic capsule. Finally, the TRUS guided 
biopsy is an invasive technique and does not allow distinguishing between CaP and BPH. 
Furthermore, there is a significant risk of infection and related consequences (fever, pain, 
hematuria and sepsis)  (50,55). 
1.5. Prostate-specific antigen as a prostate cancer biomarker 
The first references to prostate cancer date from 1649 when Riolan described the 
enlargement of prostate as a clinical manifestation of a possible tumor and related it with 
the bladder obstruction (56). At this time, the diagnosis was done based only on the family 
history and physical examination (57). Only in 1938, PAP (prostatic acid phosphatase), 
the first prostate tumor biomarker, was proposed by Gutman (58). However, despite being 
one enzyme secreted by columnar epithelium secretory cells, it can be produced by other 
organs, blood components and several non-prostatic malignancies (Table 1.2.). Therefore, 
it is a non-specific biomarker. In addition, its concentration only significantly rises when 
the adenocarcinoma of prostate is metastasized, what makes of PAP an useless biomarker 
in CaP early detection (59,60). 
Between 1960 and 1970, several researches were dedicated to the search of tumor 
specific antigens that could be useful in clinical diagnosis, with special focus in oncology 
(57). In 1960, Rubin Flocks reported some features of prostate antigens (61). The 
researcher showed that antibodies created against human prostate tissue were species- and 
tissues-specific; the antigens in benign and malignant tissue were similar and no specific 
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antigens could be isolated (62). In 1966, Mitsuwo Hara characterized a protein, “gamma-
seminoprotein” (63), and in 1970, Tien Shun Li and Carl Beling reported some antigens 
in human semen (64). It is believed that both discoveries were related with PSA; 
nonetheless, the real “discovery” of PSA is attributed to Ming C. Wang and co-workers 
when they purified and characterized PSA from prostatic tissue (65). The research group 
revealed that PSA is only produced by prostatic tissue and is present in BPH and CaP 
(65). Once discovered its potential, the applications and use of PSA have been amplified. 
PSA was approved in 1987 by the Food and Drug Administration (FDA) to monitor the 
disease status in patients with prostate cancer (66). Latter, in 1994, the same organization 
approved the PSA blood test as an easy and inexpensive screening tool to be used in 
association with DRE to detect prostate cancer (67). A serum PSA measurement of ≥ 4.0 
ng/mL is considered as a clinically relevant value where 25% of patients with values 
above this cut-off value had CaP (57), while urinary PSA has a cut-off value of 150 ng/mL 
(68). This cut-off value in urine demonstrated an impressive sensitivity of 92.5% to CaP 
diagnosis; however, due to the small number of cases analyzed, more studies have to be 
conducted to corroborate these results (69). The analysis of PSA in urine samples is also 
an important tool in distinguish amongst CaP and BPH, particularly when serum PSA is 
between 2.5 ng/mL and 10 ng/mL (68). 
 
1.5.1. Prostate cancer screening, stage and grade  
The PSA test is believed to be the best approach in the CaP early detection and 
probably the most used cancer blood test in medicine. A PSA value of ≥ 4.0 ng/mL in 
serum has been defined as abnormal and can indicate the presence of a prostatic tumor 
(70). FDA recommends an annual screening of CaP for men with 50 or more years old, 
and in African American men with more than 40 years old because ethnicity is a relevant 
factor. More than in other cancer types, age is a significant factor that influences the CaP 
development and PSA baseline values. Thus, urologists have to adjust the PSA cut-off 
levels according to age. Table 1.3. presents the reference PSA values in blood for men 
with 40-79 years old (1,71). 
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Table 1.3. PSA values of reference for men with 40-79 years old in blood (66). 
Age / (years old) Reference Values / (ng/mL) 
40 - 49 0 - 2.5 
50 - 59 0 - 3.5 
60 - 69 0 - 4.5 
70 - 79 0 - 6.5 
  
Values of PSA between 4.0 and 10.0 ng/mL in blood are considered suspicious 
and the test needs to be repeated. Also the patient needs to be supervised to check whether 
these values continue to rise, and if DRE also suggests the presence of a tumor, a TRUS 
guided biopsy has to be done to confirm diagnosis. For values above 10 ng/mL the test is 
repeated after several days for confirmation because there are some factors that can cause 
fluctuations in PSA concentrations, and a TRUS guided biopsy has to be carried out 
because for these values a patient already has a chance of 67% of CaP (72). 
The knowledge of the PSA levels also allows to evaluate the grade of the prostatic 
tumor: the higher the PSA levels, the more advanced is the disease and the larger is the 
tumor (70). PSA levels when combined with the Gleason sum score and the clinical stage 
can be used as predictors of the patient prognosis (Table 1.4.). 
The Gleason classification is a system used in the evaluation of men with CaP 
prognosis. This classification is made according to histological and cellular 
characteristics of the tumor and is the sum of histological patterns (from 1-well 
differentiated- to 5- poorly differentiated) from the two predominant cellular types in 
tumor giving a score that can vary from 2 to 10. Scores from 0-6 have a good prognosis, 
7 have moderated prognosis and scores between 8 and 10 correspond to undifferentiated 
tumor and the ones with worst prognosis (73). In what concerns the clinical stage, this is 
done to primarily evaluate the physical characteristics of the tumor and varies from T0 
(no evidence of tumor) to T4 (tumor has invaded nearby tissues). 
 
Table 1.4. Risk stratification of CaP patients according to PSA levels, Gleason grade and Clinical 
stage (69). 
Risk PSA levels / (ng/mL) Gleason grade Clinical stage 
Low < 10 ng/mL ≤ 6 T1-T2a 
Intermediate 10 - 20 ng/mL 7 T2b-T2c 
High > 20 ng/mL 8 - 10 T3-T4 
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1.5.2. Monitoring therapy and disease recurrence  
The risk stratification according to PSA levels is extremely important in the 
identification of CaP patients. For suspicious PSA levels, the first action consists on an 
active surveillance. 3-monthly PSA measurements and a re-biopsy should be done at 1 
year, and whether clinical manifestations continue to suggest the presence of a tumor, 
new clinical actions should be implemented. External beam radiotherapy (EBRT) is often 
performed, but radical prostatectomy is the most common procedure when PSA levels 
suggest that the tumor is only localized within the prostate (74). 
After radical prostatectomy, the PSA blood test is also important to check whether 
treatment was successful or whether there are signals of disease recurrence. After a few 
weeks, PSA values should decrease to undetectable concentrations (half time PSA in 
serum is approximately 2.2-3.2 days (75)) due to the removal of prostate. If the PSA 
concentration increases, there are evidences that the prostate was not totally removed or 
that the biomarker is being produced by metastases of the original tumor (74). 
The PSA blood test has been extremely useful in early diagnosis of CaP leading 
to a significant increase of tumors detection at local stages, thus resulting in a decline of 
the mortality rate. However, there are some drawbacks associated to the PSA blood test. 
PSA can also be produced by other types of tumors, by prostate enlargement and 
inflammation or even by recent sexual activity leading to false positive results and 
unnecessary surgeries (50,55). In order to overcome these drawbacks, new tests with PSA 
have been developed to increase the diagnostic accuracy, including PSA density, free 
total PSA ratio and other molecular forms, such as free PSA, proPSA and BPSA (5). 
1.5.3. Molecular characteristics  
PSA is a serine protease which is part of kallikrein related peptidases (KLKs). 
KLKs are the largest cluster of peptidases in human genome and are located in a locus of 
chromosome 19q13.3-13.4 being responsible for the expression of 15 homologous serine 
proteases with an important role in several biological processes, such as reproduction, 
inflammation blood clothing and cancer. PSA is encoded by one of these genes, the KLK3 
gene, whose expression is regulated by androgens (76). 
1.5.3.1. Biosynthesis structure  
PSA transcription and biosynthesis occur mainly in epithelial cells and 
periurethral glands in a process regulated by androgens. The KLK3 gene transcription 
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and translation yield an inactive proenzyme (pre-pro-PSA) with 261 residues. 17 of these 
are an amino acid leader sequence that is cleaved and works as a signal that directs pre-
pro-PSA to the membrane on endoplasmic reticulum (ER). In ER, the originated pro-PSA 
(244 residues) has also a pro-peptide with 7 amino acids that is cleaved in N-terminals 
between the arginine at position 7 and isoleucine at position 8 in a process of zymogen 
activation that can be autocatalytic or catalyzed by trypsin like-peptidases (76). PSA is 
its active form (237 residues) and has 5 intrachain disulfide bounds, a single asparagine-
linked oligosaccharide, a weight of 28-33 kDa, and is secreted into semen, being the most 
abundant protein in seminal fluid with a concentration between 0.5 and 2.0 mg/mL (Fig. 
1.3.) (77). Once active, PSA can diffuse into circulation and be inactivated by the binding 
of protease inhibitors or by divalent inhibitors, particularly zinc. However, PSA can also 
became inactive due to proteolytic inactivation of the carboxy-terminals of the amino acid 
residues Lysine (Lys) 145 and/or Lys 182 and circulates in an unbounded state known as 
free PSA f(PSA) (78). 
 
Figure 1.3. Schematic representation of PSA processing in epithelial cells of the prostate. 
Adapted from (75). 
 
1.5.3.2. Structure and physicochemical properties 
PSA is a serine protease glycoprotein with 28-33 kDa. PSA consists of a single 
polypeptide with 237 amino acids and a single N-linked sugar moiety at asparagine (Asn) 
61 with two fucose linkages in the inner most of N-acetylglucosamine (GlcNAc) (79). 
PSA also has in its mature form a single carbohydrate unit at Asn45 with 5 dissulfide 
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bonds which increases the total mass in 2-3 kDa. It was demonstrated that 92% of PSA is 
composed of peptides and 8% of carbohydrates, whose 4.84% is hexose, 2.87% is 
hexosamine and 0.25% is sialic acid (80). The protein consists of two 6-strand antiparallel 
β-barrels and three α-helices as depicted in Fig. 1.4.. 
 
Figure 1.4. 3D representation of PSA using light-assisted molecular immobilization technology 
(78). 
 
 The catalytic site (Serine (Ser) 195, Histidine (His) 57, and Aspartate (Asp) 102) 
is conserved and located in a cleft between two β-barrels. The sequence also contains the 
GWG motif, which is a typical pattern present in many proteins with proteolytic activity 
and the presence of the His-Asp-Ser triad and a catalytic domain similar to KLKs make 
it a serine protease. The GWG motif contains a Trp located in the β-barrel nearby the 
disulphide bond Cysteine (Cys)157-Cys 22 (81). 
PSA has 5 isoenzymes, one with 5 antibody binding sites and an isoelectric point 
ranging between 6.7-7.2 (81). Trauma, stress or a tumor can rise the PSA serum levels 
but they are usually below 0.1 ng/L, depending on its production, distribution and 
elimination. fPSA forms are cleared from blood primarily in kidneys (half time of 12 
hours). Complexed forms of PSA take more time to be eliminated (2.2-3.2 days) because 
they are larger and cannot be subjected to renal clearance (78). 
 
1.5.3.3. Physiological role of PSA in prostate and in external tissues 
PSA is a chymotrypsin-like protease with some properties that differentiate PSA 
from chymotrypsin and other serine proteases. The physiological function of PSA 
consists on liquefying seminal fluid after ejaculation in order to facilitate the sperm 
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transport in the vagina. Seminal fluid has gelified vesicles in coagulum shape and they 
are composed of seminogelins (SEMG1 and SEMG2), fibronectin, laminin and gelatin 
which are proteolytic degraded to liquefy sperm in a zinc-mediated process. In prostate, 
Zn2+ concentrations are high and the pH is alkaline, and the major role of zinc ions 
consists on inhibiting the proteolytic effect of PSA (78). 
Typically, PSA biological effects are only confined to the interior of prostate 
glands where is predominantly in an active form. In blood, PSA is an intact and non-
catalytic form due to internal cleavages or is covalently attached to α1-anthichymotrypsin 
(ACT) in levels from < 0.1 to 104 ng/mL. Levels above 102 ng/mL are found essentially 
in men with advanced prostate cancer (82). In CaP, the layer of basal cells and the 
basement membrane that surrounds prostate glands is disrupted and PSA can reach 
bloodstream and can influence neoplastic growth and metastases. PSA in bloodstream 
cleaves the insulin-like growth factor binding protein-3 (IGFBP-3), one of the major 
serum binding proteins for insulin-like growth factor-1 (IGF-1). IGF-1 is a risk factor for 
CaP and IGFBP-3 cleavages increases the IGF-1 availability increasing the proliferative 
effect of tumor cells (83). As mentioned, it has the capacity to cleave extracellular matrix 
glycoproteins, such as laminin and fibronectin, and also the urokinase-type plasminogen 
activator, that are involved in tumor invasion and metastases. Other studies suggested that 
PSA has an antiangiogenic effect and mitogen activity for osteoblasts transforming the 
growth factor-beta by proteolytic modulation of osteoblasts surface receptors (78). 
1.5.3.4. Molecular derivatives of PSA and their role in diagnosis 
Contrarily to initial findings, where PSA was considered a protein composed of 
237 amino acids, it is now known that serum PSA can occur in two forms: (i) in a 
“complexed form” with protease inhibitors; or (ii) in a free unbounded form (fPSA), and 
as shown in Fig. 5. 65%-95% of PSA occurs linked to a protease inhibitor, ACT, in a 
PSA-ACT complex that is higher in CaP patients probably because of the loss of the 
prostate integrity (5,84).  
In respect to fPSA, there are 3 distinct forms of inactive PSA. One of them, benign 
PSA (bPSA), is a clipped subform with 2 internal peptide bond cleavages at Lys 182 and 
Lys 145 and is associated with the transition zone of patients with nodular BPH (85). The 
second subform, inactive PSA, is “intact”, unclipped PSA (iPSA), that is similar to native 
PSA but with some structural changes that make it inactive. The third PSA form is 
proPSA (pPSA). pPSA comprises a 7 amino acid N-terminal pro leader peptide, [-7] 
 24 
 
proPSA, that can be cleaved to form enzymatically active PSA. [-7]proPSA can also be 
truncated by proteolytic cleavage to [-4]proPSA, [-5]proPSA and [-2]proPSA. [-
2]proPSA is of particular interest because it is not cleaved further and it accumulates in 
cancer tissues so it can have a diagnostic utility especially in the 2.5-4 ng/mL range (5). 
[-2]proPSA is also important in the prediction of CaP aggressiveness because it is a 
parameter of prostate health index, phi (𝑝ℎ𝑖 =
[−2]𝑝𝑟𝑜𝑃𝑆𝐴
𝑓𝑃𝑆𝐴
× √𝑃𝑆𝐴), which is three times 
more specific than PSA (86). 
 
 
Figure 1.5. Different fPSA percursor forms (bPSA, proPSA and intact unclipped PSA) and PSA 
complexes (PSA-ACT, PSA-API and PSA-A2M) (5). 
 
Some efforts have been done to refine and to improve the measurements of PSA 
levels aiming at gathering a more accurate diagnosis. The fPSA to tPSA ratio, usually 
known as %fPSA, has shown clinical relevance, and with a better performance of PSA 
and tPSA while differentiating between CaP and BPH when PSA values are in the grey 
zone (4-10 ng/mL) and DRE results are negative (82,87). 
1.5.3.5. Stability of total and free PSA 
The stability of PSA, important in clinical tests, is influenced by pH and 
temperature, particularly for fPSA isoforms. Biological samples containing PSA should 
be stored at 4°C and analyzed within 8 hours after collection or at -70°C and at pH of 5.5 
for latter analysis. At these conditions, PSA can be stored for 9 months with only 5% loss 
(88). tPSa is more stable and studies have shown that it can be stored at 4°C for a week, 
at -20°C in a domestic freezer for a month and even at -80°C for 7 years (89,90). 
PSA
Free PSA
bPSA
proPSA forms
-7, -5, -4, -2
Intact
uncliepped
PSA
PSA 
Complexes
PSA-ACT PSA-API PSA-A2M
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 1.6. Analytical methods for the quantification of PSA 
Since the PSA discovery and purification by Ming C. Wang in 1979 (65) and after 
the knowledge of the PSA importance in the CaP early detection, diagnosis and 
monitoring, several tests to extract, concentrate and quantify PSA, fPSA, PSA-ACT and 
tPSA were developed and are now commercially available (7). The PSA 
purification/fractionation method with ammonium sulfate is usually followed by other 
separation methods, such as gel-filtration chromatography, affinity chromatography, high 
performance liquid chromatography (HPLC) and polyacrylamide gel electrophoresis 
(91). However, for clinical purposes, immunoassays are recommended (by FDA). These 
immunoassays require  anti-PSA monoclonal antibodies that will specifically bound to 
PSA (91). There are various kinds of PSA immunoassays although the most widely used 
are the enzyme-linked immunosorbent assay (ELISA) (7), time-resolved 
immunofluorometric assay (TRIFA) (92), fluorescence microscopy (93), surface plasmon 
resonance technology (SPR) (94), and immunochromatography (95). Table 1.5. 
represents a review of literature of the immunoassays and column chromatography 
methods used for the extraction and quantification of different PSA isoforms. 
Albeit these methods have some benefits and lead to high purification factors they 
still present major disadvantages. In particular, specific and highly expensive material 
and equipment are required, as well as highly qualified and trained technicians. Moreover, 
they are usually time-consuming. In fluorescence and electrochemical-based methods, the 
analyte to be quantified has to be dyed in order to amplify the respective signal and the 
sample can be lost during these preparation steps. In addition, the prolonged exposure of 
the fluorescence dye to excitation light sources can cause photo bleaching and quenching 
of signals leading to false negative results (96). ELISA is an expensive technique, because 
of the cost of antibodies required. It also has low reproducibility and the requirement of 
signal amplification using a biochemical reaction (96). Thus, it is clear that it is necessary 
a new method, more economically viable and simpler to concentrate and quantify PSA, 
and where aqueous biphasic systems (ABS) fit. 
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Table 1.5. Comparison of literature methods for the purification/concentration/quantification of PSA isoforms from different human matrices. 
Purification/Concentration method PSA Isoform Matrix PSA recovery / (%) Ref. 
Immunoassay 
Sandwich immunochromatography technology tPSA  Blood 104.5 (95) 
ELISA tPSA Serum 99.5 (7) 
Sensitive rapid tandem bioluminescent enzyme 
immunoassay (BLIA) 
PSA/ACT Serum 85.6 (96) 
Indirect Immunosorption fPSA PSA/ACT Serum 60 (97) 
Imunoflurometric assays (TRIFA) fPSA Serum 47.5 (92) 
Column chromatography 
Thiophilic gel fPSA 
Seminal 
plasma 
96 (98) 
Ultrogel ACA44 column fPSA Serum 96 (99) 
Column of immobilized monoclonal antibodies 
(commercial antibody fragment Vivapure anti-HSA 
kit) 
free PSA 
PSA/ACT 
Serum 95 (6) 
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Chip EIA tpsa Serum 88.9 (8) 
Thiophilic gel TPSA 
Prostate 
tissue 
87 (100) 
Mixed polyclonal antibody and protein G column fPSA; PSA/ACT Serum 70 (6)  
Affinity chromatography size-exclusion and ion 
exchange chromatography, anion-exchange 
chromatography 
isoforms of PSA 
Seminal 
plasma 
55 (101) 
Ammonium sulfate precipitation 
hydrophobic interaction chromatography, gel 
filtration and anion-exchange chromatography 
isoforms of PSA 
Seminal 
plasma 
30 (102) 
PSA microarray ASSAY tpsa 
Female 
plasma 
30 (103) 
Cibacron blue affinity-based depletion fPSA; PSA/ACT Serum 5 (6) 
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1.7. Aqueous biphasic systems (ABS) for the extraction and concentration of 
proteins  
Aqueous biphasic systems (ABS) were discovered when agar and gelatin were 
mixed in water and two macroscopic and separated aqueous liquid phases were formed 
(104). However, the potential application of ABS to the extraction/separation of 
biomolecules, and as an alternative to traditional liquid-liquid extraction systems which 
use volatile and hazardous organic solvents, was only described by Albertson in 1955 
(105). ABS, when compared to traditional liquid-liquid extraction techniques, are faster, 
more economic and allow the scale-up (106). In general, in an ABS, two aqueous 
solutions of structurally different compounds are separated into two coexisting phases 
above a given concentration, and where one of the aqueous phases will be enriched in one 
of the solutes and the other in the second one. ABS can be composed of polymers and 
salts and can be classified in polymer/polymer-, polymer/salt- and salt/salt-based systems 
(9). ABS have a high water content (up to 70-90%) being thus a biocompatible media for 
biologically active products.  
ABS have already been used in the extraction and purification of cells, viruses, 
organelles, nucleic acids, lipids, amino acids, proteins, antibodies and enzymes (9,107). 
The extraction of proteins using ABS is governed by a complex phenomenon because 
inherent properties, such as the protein isoelectric point, surface hydrophobicity, molar 
mass, ionic strength, among others, influence the protein preferential partitioning. Short-
range (van der Waals) and long-range molecular interactions between the biomolecule 
and the surrounding environment have been described as the major forces ruling the 
partitioning behavior among the coexisting phases (9). Kragl and co-workers (108) 
studied the phenomena governing the activity and extraction of proteins in ionic liquid 
media and the efficiency of extraction for myoglobin, trypsin, lysozyme and bovine serum 
albumin (BSA) under different conditions. There are several other important studies 
showing the potential of ABS for the extraction and purification of Candida antarctica 
lipase A (109), Thermomyces lanuginosus lipase (110), myoglobin and ovalbumin (111), 
among others. 
 
1.7.1. Phase diagrams  
ABS are ternary systems mainly composed of water and two other solutes. The 
respective phase diagrams are usually depicted in an orthogonal representation where the 
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water concentration is omitted and as depicted in Fig. 1.6. Each ABS has a characteristic 
phase diagram describing the conditions at which the biphasic mixture is formed and at 
which ternary compositions the extractions can be performed. Thus, the phase diagrams, 
under defined pH and temperature conditions, are useful to know the necessary 
concentrations of the phase-forming components required to form a two-phase system, 
and to know the compositions of the coexisting phases and volume or weight ratio of the 
phases. ABS are characterized by a binodal curve that represents the separation between 
the miscible and immiscible regions. The biphasic region is above the binodal curve and 
the monophasic region is below it (Fig. 1.6.) (9). The tie-line (TL) for a given mixture 
denotes the composition of the coexisting phases. Figure 1.6. shows an example of a 
ternary phase diagram of an ABS, and where the binodal curve, TCB, and three mixture 
compositions at the biphasic region, X, Y and Z, are depicted. The mixtures X, Y and Z 
are along the same tie-line (TL) meaning that all the initial mixtures will present the same 
top phase equilibrium composition (TIL TSalt) and the same bottom phase composition 
(BIL BSalt).  
 
Figure 1.6. Phase diagram of an ABS: TCB = binodal curve; C = critical point; TB = tie-line; T 
= composition of the top phase; B = composition of the bottom phase; X, Y and Z = mixture 
compositions at the biphasic region. Adapted from (108).  
 
1.7.2. Ionic liquids as phase-forming components of ABS 
 
The first reported ionic liquid (IL) was synthetized by Paul Walden - 
ethylammonium nitrate, (C2H5)NH3NO3 – when the author was looking for new explosive 
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compounds (112). However, only in 1934, Charles Graenecher registered the first patent 
for an industrial application of ILs in the preparation of cellulose solutions (113). After 
these pioneering demonstrations, several patents were filled. Still, only with the 
appearance of air and water stable ILs, the research, development and new applications 
of novel ILs have significantly increased (107,108,114–116). 
ILs are salts with a general melting temperature below 100 ºC because they are 
constituted by large organic cations and usually an organic or inorganic anion. Due to 
large size of their ions, they do not easily form a crystalline structure and they are liquid 
at low temperatures (9). The ionic character associated to ILs is responsible for some of 
their remarkable features, namely a negligible vapor pressure, non-flammability, high 
thermal and chemical stabilities, and an enhanced solvation ability for organic, inorganic 
and organometallic compounds. Moreover, one of the main advantages of ILs is the fact 
that their physical state and their chemical properties can be adjusted by changing the 
cation and anion for a given application - “designer solvents”. This property promotes the 
possibility of adapting their properties, such as hydrophobicity and solution behavior, 
physical properties, and variable biodegradation ability or toxicological features (9). 
The possibility of choosing the cation and the anion in ILs leads to a potential 
number of 106 different ILs. Today more than 1000 ILs were reported in the literature, 
and approximately 300 are commercially available (117). ILs are usually classified 
according to the cation and anion chemical structures, and cations such as imidazolium-, 
pyridinium-, pyrrolidinium-, ammonium-, sulfonium-, guanidinium- and phosphonium-
based have been the most studied in the literature (117). 
            In this work, phosphonium-based ILs were investigated. The first reports of 
phosphonium-based ILs dates from the 70-80s, when Parshall (118) reported the synthesis 
of phosphonium-based ILs using stannate and germinate salts, and with the discovery of 
the tetrabutylphosphonium bromide as an ionic solvent by Knifton and co-workers (119). 
The four possible alkyl chain substituents on the phosphonium cation together with a 
multitude of available anions results in an enormous number of ionic liquids. Even so, 
tetrabutylphosphonium is the most studied phosphonium-based cation. Table 1.6. 
represents some of the most common associated anions and commercially available ILs. 
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Table 1.6. Chemical structures of phosphonium-based ionic liquids (114). 
Phosphonium-based 
ILs 
Cation Anion 
Molecular 
weight /  
(g/mol) 
Tetrabutylphosphonium 
methanesulfonate 
 
 
 
 
354.53 
Tetrabutylphosphonium 
tetrafluoroborate  
346.24 
Tetrabutylphosphonium               
p-toluenesolfunate 
 
430.62 
Tetrabutylphosphonium 
bromide  
339.33 
Tetrabutylphosphonium 
chloride  
294.88 
 
 Phosphonium-based ILs have some advantages compared with nitrogen-based 
fluids, namely higher thermal and electrochemical stabilities - useful in processes that 
operate at temperatures higher than 100 °C (120). Phosphonium cations also lack acidic 
protons so they are stable under alkaline conditions (121). They are also less dense than 
water which might be beneficial in several setups involving the settling of aqueous layers. 
Taking into account these important characteristics, phosphonium-based ILs have been 
explored as phase transfer catalysts, in electrochemical media, as solvents, in high 
temperature poly-carbonate reactions and as exfoliation agents for montmorillonite clays 
(119). 
Rogers and co-workers (118), in 2003, demonstrated that ILs can form ABS, using 
1-butyl-3-methylimidazolium chloride, [C4mim]Cl, and an inorganic salt, K3PO4. 
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However, only in 2007, IL-based ABS were applied to the extraction of proteins by Du 
et al. (116). The authors extracted proteins from human body fluids with a system 
composed of [C4mim]Cl + K2HPO4 (116). This first attempt opened a new path on the 
use of IL-based ABS to extract other proteins such as BSA, lysozyme, trypsin, myoglobin, 
horseradish peroxidase, cytochrome c, γ-globulins, haemoglobin, peroxidase and 
ovalbumin (9).  
 One of the main advantages of IL-based ABS, when compared to the more 
traditional polymer-based ABS conveys on the possibility of controlling their phases’ 
polarities by an appropriate choice of the IL ions (9). Therefore, IL-based ABS can be 
properly selected aiming at extracting and concentrating, in a single-step, a multitude of 
proteins, and in particular PSA. However, since PSA is a protein, its stability is affected 
by the protons activity or by the pH of the medium (9). Most of the ILs investigated in 
IL-based ABS do not display self-buffering characteristics and the pH is attained by 
means of a buffered salt solution (usually phosphate-based salts) (123). In this context, 
ionic liquids derived from Good’s buffers (GBs), with self-buffering characteristics, 
appear as a promising alternative. GBs are zwitterionic amino acid derivatives commonly 
used as biological buffers (124). They are chemically inert, do not interfere with the metal 
ion-protein binding, are non-toxic, are commercially available at low cost, their pKa 
values range between  6.0 and 8.0, and have a high water solubility and low solubility in 
organic solvents (125). These GBs can thus be used as precursors of IL anions given rise 
to GB-ILs. The GBs MES, TES, HEPES, CHES and Tricine, presented in Table 1.7., 
were used in this work as anions of ILs and further employed as phase-forming 
components of ABS for the extraction and concentration of PSA. In particular, ABS 
formed by these phosphonium-based ILs and an organic salt (potassium citrate) were 
investigated. Initially, phosphonium-based ILs were synthetized, with 
tetrabutylphosphonium as the common cation, combined with 5 GB-derived anions  to 
yield the ILs [P4444][MES], [P4444][TES], [P4444][HEPES], [P4444][CHES] and 
[P4444][Tricine], and characterized. Further, the respective ABS phase diagrams were 
determined at 25ºC. Finally, these systems were evaluated as extraction and concentration 
techniques for PSA. 
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Table 1.7. Chemical structures of GBs: MES: 2-(N-morpholino)ethanesulfonic acid; TES: 2-
[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid; HEPES: 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid; CHES: N-cyclohexyl-2-aminoethanesulfonic 
acid; Tricine: N-2(2-Hydroxy-1,1-bis(hydroxymethyl)ethyl)glycine. 
Good Buffer Chemical Structure 
Molecular 
weight / 
(g/mol) 
MES 
 
195.2 
TES 
 
229.2 
HEPES 
 
238.3 
CHES 
 
207.2 
Tricine 
 
179.1 
 
One of the problems addressed in PSA analyses is its low concentration in human 
fluids, and in particular, in urine. Therefore, the main goal of this work is to reach 
concentration factors of PSA at the IL-rich phase detectable by more accessible 
equipment and less laborious techniques. For this purpose, it is necessary to test different 
initial concentrations of IL and organic salt, along the same tie-line, and to evaluate the 
extraction efficiencies and concentration factors experimentally achievable. The 
promising ABS were then tested with human urine by adding PSA at known 
concentrations. 
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2. Extraction of PSA 
using phosphonium-
based ILs + salt ABS 
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2.1. Introduction 
Proteins are a wide group of important biomolecules. They are present as enzymes, 
antibodies, hormones, transport and structural proteins, among others (126). Due to their 
admirable properties, there is an increasing interest in the production and extraction of 
proteins for a broad range of fields (127). Proteins are helpful in biochemical and medical 
research, for example as biomarkers of diseases (72), and in textile, food and 
pharmaceutic industries (127). In this context, many efforts have been carried out to 
optimize the extraction and purification procedures for proteins, because, due to their poor 
stability, changes in the microenvironment can cause their denaturation leading to protein 
unfolding and inactivation. It is therefore of critical relevance, in extractive procedures 
of proteins, to maintain their three-dimensional structure (127). Thereby, the efforts are 
directed to develop not just a biocompatible, but also cheaper, sustainable and one-step 
platform for the extraction and purification of proteins that can be easily scaled-up to an 
industrial level (123). Prostate specific antigen (PSA) is a glycoprotein of great interest 
in medical research as the gold-standard prostate cancer (CaP) biomarker (2). Values 
above 4 µg/L in human serum are considered suspicious and patients have to be subjected 
to more tests to confirm the diagnosis (70). However, the cut-off for serum PSA is below 
the detection limit of most quantification equipment and the conventional tests and 
techniques used for clinical analyses present serious drawbacks. As stated in Chapter 1.6., 
the commonly used tests and techniques to quantify PSA are immunoassays, such as 
ELISA (91), which requires the use of highly cost antibodies, and a large investment in 
time and resources - reason why these assays have to be performed in clinically specific 
laboratories. Moreover, in fluorescence and electrochemical-based methods, the analyte 
to be quantified has to be dyed to amplify the signal which can lead to sample lost in 
preparation steps. The prolonged exposure of the fluorescent dye to excitation light 
sources can also cause photo bleaching and quenching of the signals leading to false 
negative resources (96). 
 It is clear that a new platform for the one-step extraction and concentration of 
PSA, without changes in the protein 3D structure, and by a more economic and simple 
way, is a real need towards the use of less expensive and more accessible equipment for 
the PSA quantification in clinical laboratories. The commonly used protein purification 
methods include electrophoresis, ionic exchange and affinity chromatographies, and 
precipitation with salts or solvents, such as ammonium sulphate or ethanol (128,129). 
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Nevertheless, these methods, in addition to be high time and cost consuming, employ 
volatile organic compounds hazardous to human health and for the environment (130). 
All of these drawbacks can cause the loss of the 3D structure of proteins, reason for what 
the use of ABS with ILs has been emerged in recent years as an efficient and clean 
alternative over the traditional organic-water extraction systems (9). Moreover, the 
stability of proteins is strongly affected by the proton activity of the supporting solution 
and has an optimum pH that can be adjusted by the addition of a proper biological buffer. 
It is generally accepted that, at appropriate concentrations, hydrophilic ILs tend to 
dissociate in aqueous solutions, fully or partly, and into ions which form neutral or very 
weakly basic solutions (131). Therefore, the addition of a buffer into aqueous IL 
solutions, when dealing with protein stability, will not provide an adequate pH control 
since the ILs acidity or basicity can swamp the buffer effect (131). Taking into account 
the multitude of combinations between cations and anions in ILs, the synthesis of ILs 
with buffering characteristics seems to be the step to follow. 
 Norman Good and his research team (125) designed biological buffers (Good’s 
buffers, GBs), zwitterionic amino acid derivates, and these can be used as anion or cation 
precursors of ILs. It was suggested that these biological buffers act as protein structure 
stabilizers by a hydration phenomenon (131). These statements suggested the possibility 
of creating new self-buffering ILs with protein stabilization characteristics, and that 
where investigated in this work as phase-forming components of aqueous biphasic 
systems (ABS) for the extraction and concentration of PSA. As a first step, novel GB-ILs 
were synthesized and characterized. Their pH-profiles were already demonstrated 
and they act as adequate buffers in the 6-8 pH region (132). The GB-ILs adopted in 
this work are based on anions derived from N-(2-hydroxy-1,1-
bis(hydroxymethyl)ethyl)glycine (Tricine), 2-[1,3-dihydroxy-2-
(hydroxymethyl)propanyl]amino]ethanesulfonic acid (TES), N-cyclohexyl-2-
aminoethanesulfonic acid (CHES), N-cyclohexyl-2-aminoethanesulfonic acid (HEPES), 
and 2-(N-morpholino)ethanesulfonic acid (MES), coupled with the common 
tetrabutylphosphonium ([P4444]
+) cation. These GB-ILs were then used as constituents of 
ABS, combined with potassium citrate in aqueous media, as alternative extraction media 
for PSA. Initially, the ternary phase diagrams, tie-lines (TLs) and tie-line lengths (TLLs) 
were determined at 25ºC. Then, these systems were investigated as liquid-liquid 
extraction platforms for PSA. 
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2.2. Experimental Section 
2.2.1. Chemicals 
The salt potassium citrate tribasic monohydrate (K3C6H5O7·H2O, purity ≥ 99 
wt%) was obtained from Sigma-Aldrich Chemical Co. (USA). PSA (purity ≥ 95 %) was 
obtained from Sigma-Aldrich Chemical Co.. Methanol (purity > 99.9%) was obtained 
from Fisher Scientific. Acetonitrile (purity > 99.7%) was supplied from Lab-Scan. The 
buffers required for the ILs synthesis, namely CHES (purity > 99 wt%), HEPES (purity 
> 99.5 wt%), MES (purity> 99 wt%), Tricine (purity > 99 wt%) and TES (purity > 99 
wt%) were purchased from Sigma-Aldrich Chemical Co.. The cation precursor, 
[P4444][OH] (40 wt% in H2O), was also supplied by Sigma–Aldrich Chemical Co.. 
Dimethyl sulfoxide (DMSO, purity > 99.9 wt%) and deuterium oxide (D2O purity > 99.9 
wt%) were obtained from Sigma–Aldrich Chemical Co.. Purified water passed through a 
reverse osmosis and a Milli-Q plus 185 water purifying system was used in all 
experiments. For quantification of PSA using the BLItz Pro System, Super Streptavidin 
biosensors acquired from VWR were used. 
 
2.2.2. Experimental Procedure       
2.2.2.1. Synthesis and characterization of the Good’s buffers ionic liquids 
The GB-ILs were synthesized via neutralization of the base with the appropriate 
acid. A slightly excess of an equimolar aqueous solution (1:1.1) of buffer was added drop-
wise to a tetrabutylphosphonium hydroxide solution. The mixture was stirred 
continuously for at least 12 h at room temperature (≈ 25 ºC) (Fig. 2.1. A) to produce the 
ionic liquid and water as by-product. The mixture was then evaporated at 50-60 °C under 
reduced pressure and which gives rise to a viscous liquid (Fig. 2.1. B). A mixture of 
acetonitrile and methanol (1:1, v:v) was added to the viscous liquid and then vigorously 
stirred at room temperature for 1 h (Fig. 2.1. C). The solution was then filtered to remove 
any excess buffer. The solvent mixture was evaporated and the GB-IL product was dried 
in vacuum (10 Pa) for 3 days at room temperature (Fig. 2.1. D). The water content in each 
GB-IL was measured by Karl-Fischer (KF) titration, using a KF coulometer (Metrohm 
Ltd., model 831). The chemical structures of the GB-ILs were confirmed by 1H and 13C 
NMR spectroscopy (Bruker AMX 300) operating at 300.13 and 75.47 MHz, respectively. 
Chemical shifts are expressed in δ (ppm) using tetramethylsilane (TMS) as internal 
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reference and D2O as deuterated solvent. The ILs synthetized in this work showed high 
purity level without signs of decomposition. 
  
 
Figure 2.1. GB-ILs synthesis. An equimolar excess of the aqueous solution of buffer was added 
to [P4444]OH solution (A). The mixture was dried at 50-60 °C under reduced pressure in a 
Carrousel 6 plus reaction station (B). A mixture of acetonitrile and methanol (1:1, v:v) was added 
to the viscous liquid and then vigorously stirred at room temperature for 1 h (Fig. 2.1. C). The 
solvent mixture was evaporated and the GB-IL was dried in vacuum (10 Pa) for 3 days at room 
temperature (D). 
2.2.2.2. Phase diagrams and tie-lines (TLs) 
 The binodal curve of each ABS was determined through the cloud point titration 
method at 25 (± 1) ºC and atmospheric pressure. The experimental procedure adopted has 
been validated in previous reports (123,133). Repetitive drop-wise addition of the 
aqueous salt solution (K3C6H5O7 at 60 wt %) to the IL (circa 80 wt %) aqueous solution 
was carried out until the detection of a cloudy biphasic solution, followed by the drop-
wise addition of water until the finding of the monophasic region. The opposite addition 
was also attempted aiming at gathering the maximum number of points to describe each 
binodal curve. This procedure was carried under constant stirring. Each mixture 
composition was determined by the weight quantification of all components added within 
an uncertainty of ± 10-4 g (using an analytical balance, Mettler Toledo Excellence XS205 
DualRange).  
The tie-lines (TLs) of each phase diagram, and at the mixtures compositions for 
which the extraction of PSA was carried out, were determined by a gravimetric method 
originally described by Merchuk et al. (134). The selected mixture, at the biphasic regime, 
was prepared by weighting the appropriate amounts of IL + salt + water and further 
vigorously stirred. Then, the mixture was submitted to centrifugation for 10 min at 5000 
A B C D
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rpm and at controlled temperature of (25 ± 1) °C. After centrifugation, the sample was 
left in equilibrium for more 10 min at (25 ± 1) °C to guarantee the equilibration of the 
coexisting phases. After this period, each phase was carefully separated and weighted.  
The experimental binodal curves were fitted using Eq. 1 (134), 
[IL] = 𝐴𝑒𝑥𝑝[(𝐵[Salt]0.5) − (𝐶[Salt]3)]     (1) 
where [IL] and [Salt] are the IL and salt weight fractions percentages, respectively, and 
𝐴, 𝐵 and 𝐶 are fitted constants obtained by least-squares regression. 
Each individual TL was determined by a weight balance approach through the 
relationship between the top weight phase composition and the overall system 
composition. For the determination of TLs the following system of four equations (Eqs. 
2 to 5) was used to estimate the concentration of IL and salt at each phase ([IL]IL, [IL]Salt, 
[Salt]Salt and [Salt]IL) (134): 
[IL]IL = 𝐴𝑒𝑥𝑝[(𝐵[Salt]Salt
0.5 ) − (𝐶[Salt]Salt
3 )]     (2) 
[IL]Salt = 𝐴𝑒𝑥𝑝[(𝐵[Salt]Salt
0.5 ) − (𝐶[Salt]Salt
3 )]    (3) 
[IL]IL =
[IL]M
𝛼
− (
1−𝛼
𝛼
) [IL]Salt       (4) 
[Salt]IL =
[Salt]M
𝛼
− (
1−𝛼
𝛼
) [Salt]Salt      (5) 
where the subscripts salt and IL designate the salt- and IL-rich phases, respectively, and 
M is the initial mixture composition. The parameter α is the ratio between the top weight 
and the total weight of the mixture. The solution of this system provides the concentration 
(wt %) of the IL and salt in the top and bottom phases, and thus the, TLs can be easily 
represented. 
For the calculation of the tie-line length (TLL), Eq. 6 was applied.  
TLL = √([Salt]IL − [Salt]Salt)2 + ([IL]IL − [IL]Salt)2    (6) 
 
All the calculations considering the mass fraction or molality of the citrate-based salt 
were carried out discounting the complexed water. In all systems, the IL-rich phase 
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corresponds to the top phase while the bottom phase is mostly enriched in the organic 
salt. 
2.2.2.3. Partition of PSA 
The ternary mixtures compositions used in the partitioning experiments were 
chosen based on the phase diagrams determined in this work for each IL-salt-water 
system. Different mixture compositions (30 wt% salt + 30 wt% IL + 40 wt% H2O and 30 
wt% salt + 40 wt% IL + 30 wt% H2O) were also studied to evaluate the effect of the 
concentration of the phase-forming components through the extraction of PSA. Aqueous 
solutions of PSA at concentrations of circa 50 ng.mL-1 were used as the “water” added to 
each ABS. The used PSA concentration was chosen after optimization using BLItz® Pro 
system. Each mixture was vigorously stirred, centrifuged for 10 min, and left to 
equilibrate for more 10 min at (25 ± 1) °C to reach the PSA complete partitioning between 
the coexisting phases. After, a careful separation of the phases was performed and the 
amount of PSA in each phase was quantified using a BLItz® Pro system. The BLItz® Pro 
system is a highly precise and sensitive immunoassay tool to quantify specific proteins 
and which allows to infer on the protein stability. The BLItz® Pro system is based on the 
principle of antibody-antigen interactions. The Super Streptavidin Biosensors employed 
are coated with ultra-high density Streptavidin and allow the measurements of kinetic 
interactions (through the exploitation of the high affinity streptavidin-biotin interactions).  
 
Figure 2.2. Blitz® PRO System and Super Streptavidin Biosensors. 
The quantification of PSA in each phase was carried out by an external standard 
calibration method in the range of 1 to 100 ng.mL-1 of protein. At least three independent 
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ABS were prepared and 2 samples of each phase were quantified using a calibration curve 
specifically determined for this purpose (Appendix A).  
The percentage extraction efficiency of PSA, 𝐸𝐸PSA%, is the percentage ratio 
between the amount of protein in the IL-rich aqueous phase to that in the total mixture, 
and is defined according to Eq. (7): 
 
𝐸𝐸PSA% =
𝑤𝑃𝑆𝐴
𝐼𝐿
𝑤𝑃𝑆𝐴
𝐼𝐿 +𝑤𝑃𝑆𝐴
𝑆𝑎𝑙𝑡   100 
 
where 𝑤𝑃𝑆𝐴
𝐼𝐿  and 𝑤𝑃𝑆𝐴
𝑆𝑎𝑙𝑡 are the total weight of protein in the IL-rich and in the salt-rich 
aqueous phases, respectively.  
 Computer proteomics is a growing area on the bioinformatics field typically used 
to study and predict the structural and functional organization of proteins. Nowadays, 
computer proteomics is performed based on thousands of databases, such as PROSITE, 
PFAM, BLAST, BLAST and UNIPROT (135). The Discovery Studio software, used in 
this work, allows the simulation of molecular mechanisms, antibodies modeling, and 
structure-, pharmacophore- and ligand based-designs, x-ray data processing and 
macromolecules design and analyses. In this work, Discovery studio was used for the 
macromolecule design and analysis with the purpose of performing sequence alignments 
and to generate the 3D structure model of PSA and, at the end, to study the macromolecule 
interactions with the phase-forming components of ABS.  
2.3. Results and discussion 
2.3.1. Characterization of the synthetized ionic liquids 
 The macroscopic appearance (Fig. 2.3.) and NMR characterization data for each 
GB-IL are described below. The chemical structures of the synthesized ILs are depicted 
in Table 2.1.. 
(7) 
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Figure 2.3. Macroscopic appearance of the synthesized Good's Buffer ionic liquids at 25ºC. From 
the left to the right: [P4444][MES], [P4444][TES], [P4444][CHES], [P4444][HEPES], [P4444][Tricine]. 
[P4444][MES]: From the MES buffer (48.5 mmol), this compound was obtained as a white 
solid. Water content < 0.05 wt%. 1H NMR (300 MHz, D2O/TSP): 3.63 (t, 4H), 2.99 (t, 
2H), , 2.72 (t, 2H),  2.50 (t, 4H), 2.02 (m, 8H), 1.27-1.42 (m, 16H), 0.78 (t,12H,). 13C 
NMR (75.47 MHz, D2O/TSP): 68.80, 55.44, 55.11, 50.02, 26.28, 20.80, 20.16, 15.44. 
[P4444][TES]: From the TES buffer (45.1 mmol), this compound was obtained as a 
transparent viscous liquid. Water content < 0.05 wt%. 1H NMR (300 MHz, D2O/TSP): 
3.31 (s, 6H),  2.82 (s, 2H), 2.57 (t, 2H), 2.10 (m, 8H), 1.29-1.49 (m,16H), 0.79 (t, 12H). 
13C NMR (75.47 MHz, D2O/TSP): 60.65, 57.63, 51.58, 37.69, 26.28, 20.83, 20.17, 15.46. 
[P4444][CHES]: From the CHES buffer (47.2 mmol), this compound was obtained as a 
transparent viscous liquid. Water content <0.05 wt%.  1H NMR (300 MHz, D2O/TSP); 
1H NMR (300 MHz, D2O/TSP); 2.95 (m, 2H), 2.38-2.47 (m, 1H), 2.02 (m, 8H), 1.28-1.45 
(m, 16H,), 0.94 (m, 10H), 0.78 (t, 12H). 13C NMR (75.47 MHz, D2O/TSP): 63.37, 63.09, 
53.42, 39.56, 26.28, 26.08, 25.60, 20.30, 20.15, 15.43. 
[P4444][HEPES]: From the HEPES buffer (44.3 mmol), this compound was obtained as 
a yellowish white solid. Water content < 0.05 wt%. 1H NMR (300 MHz, D2O/TSP): 3.59 
(t,4H), 2.97 (t, 2H), 2.94 (t, 2H), 2.67 (t, 2H), 2.46 (t, 8H), 2.03 (m, 8H), 1.28-1.45 (m, 
16H), 0.79 (t, 12H). 13C NMR (75.47 MHz, D2O/TSP): 61.59, 60.87, 55.02, 54.78, 54.19, 
50.39, 26.29, 20.80, 20.16, 15.44. 
[P4444][Tricine]: From the Tricine buffer (50.3 mmol), this compound was obtained as 
white solid. Water content < 0.05 wt%. 1H NMR (300 MHz, D2O/TSP): 3.37 (s, 6H), 3.12 
(s, 2H), 2.00 (m, 8H), 1.27-1.44 (m, 16H), 0.77 (t. 12H). 13C NMR (75.47 MHz, 
D2O/TSP): 182.71, 63.12, 62.97, 47.68, 26.28, 20.79, 20.15, 15.42. 
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Table 2.1. Chemical structures and molecular weight (g/mol) of the synthesized GB-ILs 
([P4444][MES], [P4444][TES], [P4444][HEPES], [P4444][CHES], [P4444][Tricine]). 
GB-IL Chemical Structure 
Molecular 
weight / 
(g/mol) 
[P4444][MES] 
 
454.6 
[P4444][TES] 
 
488.6 
[P4444][HEPES] 
 
497.7 
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[P4444][CHES] 
 
466.6 
[P4444][Tricine] 
 
438.5 
 
2.3.2. Phase Diagrams and Tie-lines 
The new phase-diagrams, at 25 °C and at atmospheric pressure, for the systems 
composed of water, K3C6H5O7 and [P4444][GB] ([P4444][Tricine], [P4444][CHES], 
[P4444][MES], [P4444][HEPES] and [P4444][TES]) are illustrated in Figure 2.4. 
 
Figure 2.4. Phase diagrams for the systems composed of IL + K3C6H5O7 + H2O at 25ºC and 
atmospheric pressure (in wt%) with the corresponding binodal data adjusted by Eq. 1: 
[P4444][Tricine] (); [P4444][HEPES] (); [P4444][TES] (); [P4444][MES] ();[P4444][CHES] ();  
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The experimental data are shown in weight fraction to allow a direct screening of 
the mixture compositions required to form two-phase systems able to carry out the PSA 
extraction and concentration. The detailed experimental data corresponding to the ternary 
phase diagrams determined in this work are presented in Appendix B. 
In all ABS, the biphasic region is positioned above the solubility curve while the 
monophasic region is localized below. Diagrams with the largest area above the binodal 
curve have therefore a higher ability to form two phases, i.e., the IL is more easily salted-
out by the salt. Therefore, from Figure 2.4., and for instance at 10 wt% of K3C6H5O7, the 
ability of GB-ILs to create ABS follows the order: [P4444][CHES] > [P4444][MES] > 
[P4444][HEPES] ≈ [P4444][TES] > [P4444][Tricine]. 
The formation of an ABS depends on the type of IL and its concentration, type of 
salt and its concentration, temperature, pH or pressure. The two-phases forming ability in 
each IL-based system is a result of complex and competing interactions occurring 
between the solutes and water or between the phase-forming components (9). Once the 
concentration of salt and IL, temperature, pressure and pH are maintained constants, the 
ABS formation is a result of the type of salt and IL, which means that the ABS studied 
reflect the competition between the salting-out ions and the IL ions for the formation of 
hydration complexes. The citrate-based salt is composed of a trivalent charged anion and 
is a strong salting-out species according to the Hofmeister series (136). Therefore, it has 
a high affinity for water, and thus, there is a preferential exclusion of the IL ions from the 
aqueous solution promoting the two-phases separation. 
The ILs investigated are formed by a tetrabutylphosphonium ([P4444]
+) cation and 
GB-derived anions. The cation is the same for all the investigated ILs and their effect 
cannot be appraised from the obtained phase diagrams. However, it was already 
demonstrated that [P4444]-based ILs display a high ability to promote the phase split when 
compared with ammonium-, pyridinium- and imidazolium-based ionic liquids (137). 
[P4444]-based salts have highly shielded charges, located mostly on the heteroatom 
surrounded by four alkyl chains, thus leading to a higher tendency towards their salting-
out from aqueous media. On the other hand, the anions have a higher aptitude for creating 
hydration complexes because they are more polarizable and present more diffuse valence 
electronic distribution (138). This means that anions, when compared with cations, have 
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a more relevant influence in ABS formation and behavior. Anions with lower hydrogen-
bond basicity values present lower ability to form coordinative hydrogen-bonds and to 
create hydration complexes, and therefore are more easily salted-out by conventional salts 
(138). The hydrogen-bond basicity values for the ILs used in this work have not been 
reported up to date; yet, relevant conclusions can be achieved using the octanol-water 
partition coefficients (Kow) of each GB. The higher the value of log(Kow) the higher the 
affinity of the anion for the octanol-rich phase, meaning that it has a lower affinity for the 
water-rich phase and to be hydrated. In this context, higher log(Kow) values correspond to  
anions that are more easily separated by a salting-out phenomenon. As expected, the ILs 
composed of anions with –OH groups and lower values of log(Kow) ([Tricine]-: -5.25; 
[TES]-: -4.48; [HEPES]-: -3.11) (132) are those that correspond to ILs that are more 
distant from the axis in Figure 2.4.. Thus, these GB-ILs require higher amounts of salt for 
phase separation. On the other hand, GBs with no –OH groups display higher log(Kow) 
values ([MES]-: -2.48; [CHES]-: -0.59) (132) reflecting their lower aptitude to hydrogen-
bond with water and higher ability for liquid-liquid demixing in ABS.  
For the studied systems, the experimental binodal data were further fitted by the 
empirical relationship described by Eq. 1. The regression parameters A, B and C, were 
estimated by the least-squares regression method, and their values and corresponding 
standard deviations (σ) are provided in Table 2.2. The respective correlations are also 
depicted in Figure 2.4 in combination with the experimental data. In general, good 
correlation coefficients were obtained for all systems, indicating that these fittings can be 
used to predict data in a given region of the phase diagram where no experimental results 
are available.  
Table 2.2. Correlation parameters used to describe the experimental binodal data by Eq. 1 and 
respective standard deviations (σ) and correlation coefficients (R2). 
IL A ± σ B ± σ 105 (C ± σ) R2 
IL + K3C6H5O7 + water 
[P4444][MES] 98.3 ± 0.54 -0.327 ± 0.022 3.96 ± 0.06 0.9996 
[P4444][CHES] 111.9 ± 2.49 -0.450 ± 0.009 10.5 ± 0.44 0.9929 
[P4444][HEPES] 105.1 ± 1.19 -0.295 ± 4.257 2.78 ± 0.08 0.9978 
[P4444][Tricine] 105.1 ± 5.10 -0.248 ± 0.016 1.71 ± 0.02 0.9992 
[P4444][TES] 99.6 ± 0.51 -0.356 ± 0.007 5.40 ± 0.29 0.9971 
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The experimental TLs, along with their respective length (TLL), are reported in 
Table 2.3. The TLs obtained for each systems are depicted in Figure 2.6. In general, the 
TLs are closely parallel to each other. 
Table 2.3. Data for the tie-lines (TLs) and tie-line lengths (TLLs). Initial mixture compositions 
are represented as [Salt]M and [IL]M, whereas [Salt]Salt and [IL]Salt are the compositions of IL and 
salt at the IL-rich phase, respectively, and vice-versa. 
Weight fraction composition / (wt %) 
IL + K3C6H5O7 + water 
IL [IL]IL [salt]IL [IL]M [salt]M [IL]salt [salt]salt TLL 
[P4444][MES] 
65.71 1.51 29.42 20.48 2.89 34.36 70.89 
90.81 0.06 29.36 30.33 0.37 44.12 100.60 
94.29 0.01 30.21 39.87 0.27.10-3 58.64 111.04 
[P4444][CHES] 
67.45 1.26 29.70 19.83 0.11 34.38 75.04 
75.58 0.76 29.64 30.25 0.17×10-4 49.27 89.81 
93.56 0.16 30.11 39.95 0.18×10-8 58.83 110.44 
[P4444][HEPES] 
57.51 4.14 29.89 20.14 6.59 33.63 57.80 
83.11 0.63 30.24 29.49 0.95 46.00 93.84 
90.97 0.24 29.72 40.13 0.03 59.46 108.52 
[P4444][Tricine] 
52.11 7.75 30.08 24.73 4.42 44.50 60.20 
70.02 2.64 30.45 29.71 2.53 48.78 81.75 
94.31 0.19 29.78 40.11 0.54 58.20 110.26 
[P4444][TES] 
50.61 5.97 30.28 19.70 0.39 39.87 60.59 
93.58 0.05 30.69 29.89 0.08 44.32 103.45 
96.00 0.02 30.43 39.48 0.11×10-3 57.80 112.05 
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Figure 2.5. Phase diagrams and TLs (■) and adjusted binodal data using Eq. 1 (-), at 25ºC and 
atmospheric pressure, for the ternary systems composed of K3C6H5O7 + water + [P4444][MES] 
(); [P4444][CHES] ();  [P4444][HEPES] (); [P4444][Tricine] (); [P4444][TES] (). 
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2.3.3. Partition of PSA 
 The driving forces that influence the proteins migration are still not clear, but have 
been described as mainly including electrostatic interactions between the negatively 
charged amino acids residues of the proteins surface and the cation of the ionic liquid 
(108,116) and hydrophobic interactions (139). However, hydrogen bonding, π⋅⋅⋅π 
interactions between the aromatic groups and dispersive-type interactions between the 
aliphatic groups also affect proteins extraction and partitioning and cannot be discarded. 
 The extraction efficiencies of PSA in ABS composed of [P4444][GB] + K3C6H5O7 
at given mixture compositions are shown in Table 2.4. PSA was added to each system as 
an aqueous solution at a concentration circa 50 ng.mL-1. The obtained results show that 
PSA is completely extracted to the top phase in all the studied systems since no PSA was 
found in the bottom phase. However, the results of the mass balance of protein reveal 
small losses of PSA, and between 1.27 – 5.16 % in the 30 wt% of IL + 30 wt% of salt, 
and between 5.05 – 10.73% in the 30 wt% of IL + 40 wt% of salt mixture compositions.  
As stated out before, PSA is a labile protein and may suffered some denaturation. 
However, these small losses are not significant after the concentration step that will be 
shown latter and for which PSA can be identified and quantified by HPLC. 
Table 2.4. Extraction efficiency of PSA (EEPSA%) at 25º C in the ABS composed of ILs and 
K3C6H5O7.  
IL 
Weight fraction composition / (wt %) 
EEPSA% 
Loss of 
protein / 
(wt%) 
IL Salt 
[P4444][MES] 30.35 ± 0.15 30.84 ± 0.53 100 -4.71 
[P4444][CHES] 30.13 ± 0.25 30.54 ± 0.63 100  -1.27 
[P4444][HEPES] 30.16 ± 0.35 30.44 ± 0.29 100  -8.00 
[P4444][Tricine] 30.90 ± 0.28 30.70 ± 0.31 100 -9.74 
[P4444][TES] 29.95 ± 0.24 30.08 ± 0.69 100 -5.16 
[P4444][MES] 30.01 ± 0.04 40.03 ± 0.14 100 -5.87 
[P4444][CHES] 29.94 ± 0.13 40.12 ± 0.57 100 -5.05 
[P4444][HEPES] 30.09 ± 0.34 39.97 ± 0.27 100 -10.21 
[P4444][Tricine] 30.37 ± 0.17 39.98 ± 0.07 100 -10.73 
[P4444][TES] 30.63 ± 0.37 39.85 ± 0.17 100 -6.32 
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The driving forces in the PSA partitioning were investigated using the Discovery 
Studio software. Figure 2.6. depicts the PSA secondary structure (1) and their secondary 
structure with its active site highlighted with a red sphere (2).  
 
Figure 2.6 PSA secondary structure (1) and their active site (2) (using the Discovery Studio 
software). 
 Figure 2.7. shows the surface of PSA and their sites for π⋅⋅⋅π  (3), electrostatic (4), 
hydrophobic (5) and hydrogen-bonding interactions (6). It can be seen that hydrophobic 
interactions are the most predominant surface interactions especially in the PSA active 
site. These statements are in close agreement with the obtained data. Using the octanol-
water partition coefficients (log(Kow)) presented before, and by analyzing the loss of 
protein in each systems and displayed in Table 2.4., it is seen that ionic liquids with higher 
Kow values, i.e., more hydrophobic compounds and thus with stronger interactions with 
the hydrophobic active site of PSA, are those that lead to lower losses of protein (as 
observed with the [Tricine]-based IL). 
1 2
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Figure 2.7. Discovery Studio analyses of the surface PSA interactions. (3) aromatic interactions; 
(4) electrostatic interactions; (5) hydrophobic interactions; (6) hydrogen-bonding interactions. 
 Few works have been reported with the use of GB-ILs for proteins extraction 
(131,140). Extraction efficiencies between 85-100% of BSA and antibodies were also 
achieved with ammonium- (131) and cholinium-based GB-ILs (140). However, in 
addition to the hydrophobic interactions, salting-out effects may also have a crucial 
impact in the complete extractions achieved in a single-step. The salt used is a strong 
salting-out species since it has a high-charge density anion with the capacity to create 
hydration complexes. Therefore, PSA can also be “excluded” from the salt-rich phase to 
the IL-rich phase, and as observed with previous systems were a strong salting-out species 
was used (131). 
 2.4. Conclusions  
 The obtained data can revolutionize the world of CaP early-stage diagnosis since 
this is the first work were 100% extraction efficiencies PSA for one of the aqueous phases 
were obtained. Up to now, no works have been published aiming the extraction of PSA 
with IL-based ABS, and only one work has been identified and which evaluated the PSA 
partition coefficient using polymer-based ABS (141). However, these published results 
are far from the complete extraction in a single-step (141). Therefore, the use of ILs 
certainly allows the one-step complete extractions of PSA. Once guarantying the 100% 
3 4
5
6
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of extraction of PSA for the top phase, this cancer biomarker can certainly be concentrated 
by reducing the amount of the top (IL-rich) phase while maintaining the mixture 
composition of the coexisting phases. The next section shows the results on the 
concentration of PSA so that it can be quantified by a more expedite equipment, such as 
HPLC. 
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3. Concentration of PSA 
using model IL-based 
ABS  
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3.1. Introduction 
 One of the major concerns addressed to the biomarkers analysis and their respective 
identification and/or quantification relays on their low concentration in body fluids. The 
quantification of PSA, as pointed out before, requires the use of immunoassays that can 
only be performed in specific clinical laboratories by skilled personnel (142). In addition, 
immunoassays require the use expensive antibodies and are time-consuming techniques 
(142). Moreover, different laboratories use antibodies from different sources which lead to 
significant dissimilarities in the results (142). Thus, it is difficult to establish large 
screening programs in urologic clinics and general medical practices based on 
immunoassays (142). 
 IL-based ABS represent a potential alternative for the commonly used techniques 
for PSA analysis in terms of compatibility, time and cost-consuming, as an easy-to-
implement process and also as a concentration technique. It has been shown that IL-based 
ABS can be used to concentrate bisphenol A from biological fluids up to 100-times (143) 
and ethinylestradiol (EE2) from wastewaters up to 1000-times in a single-step. These 
results can be extrapolated to tumor biomarkers and can revolutionize the world of clinical 
analyses by the extraction and concentration of cancer biomarkers in human fluids allowing 
the use of more expedite and accessible equipment.  
The cut-off value of PSA in urine is 150 ng/mL (144), and considering the detection 
limit of the HPLC used, concentration factors up to 175-fold are required. Nevertheless, 
and to guarantee no underestimated CaP diagnoses, concentration factors up to 250 were 
the main goal and were investigated herein. 
3.2. Experimental section 
 3.2.1. Chemicals 
 The salt, ILs and water used in this section were described in Chapter 2. PSA 
(purity ≥ 95%) was obtained from Sigma-Aldrich Chemical Co.. For the HPLC analyses, 
sodium phosphate monobasic (NaH2PO4, purity: 99 – 100.5 %), sodium phosphate 
dibasic heptahydrated (Na2HPO4∙7H2O, purity: 98.2 – 102.0 %) and sodium chloride 
(NaCl) were acquired from Sigma–Aldrich and used. 
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 3.2.2. Experimental procedure 
 3.2.2.1. Lever-arm Rule  
The lever-arm rule was used to determine the weight percentages ratio of the 
coexisting phases in the respective phase diagrams. Several extractions were carried out 
at different compositions in the same TL which correspond to different concentration 
factors. Along the same TL, the composition of the phases is maintained while varying 
the weight or volume ratio between them. First, a fixed and long TL was selected, and a 
weight balance approach was used to determine the weight fraction of each phase-forming 
component ([P4444][GB] and K3C6H5O7) to be used in each extraction corresponding to a 
given concentration factor.  
 For each mixture, the salt and ionic liquid percentages were varied to obtain the 
desired concentration factor (CF, equation (8)), 
 
CF= wH2O wIL⁄      (8) 
 
where 𝑤𝐻2𝑂 and 𝑤IL𝑝ℎ𝑎𝑠𝑒 correspond to the weight of the aqueous solution containing 
PSA initially added to the system and the weight of the IL-rich phase in the biphasic 
mixture obtained. 
3.2.2.2. Concentration factors of PSA 
 The ternary mixtures compositions used in partitioning experiments were chosen 
based on the phase diagrams determined and presented in Chapter 2.3.2.. Several ternary 
mixtures were prepared within the biphasic region with the theoretical weight percentages 
ratio of salt, IL and H2O/PSA provided by the lever-arm rule for concentrations factors 
of 5, 20, 50, 100, 150, 200 and 250-fold. ABS were first prepared as a control without 
adding PSA, and once achieved the CF of 250-fold the extractions were performed adding 
an aqueous solution of PSA at a concentration of 150 ng/mL (the cut-off value found in 
urine (68)). Each mixture was vigorously stirred, centrifuged for 10 min and left to 
equilibrate for at least 10 min at (25 ± 1) ° C. 
 The mixtures were carefully separated and weighted to check the predicted CF 
according to equation (8). PSA was then quantified in each phase by SE-HPLC. 
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3.2.2.3. Size-exclusion HPLC (SE-HPLC) 
After a careful separation of the phases both of them were analyzed by SE-HPLC. 
A phosphate buffer solution (1000 mL) was prepared using 47 mL of a Solution A (27.8g 
NaH2PO4), 203 mL of a Solution B (53.65g Na2HPO4∙7H2O) and 35g of NaCl. Each 
phase was diluted at a 1:9 (v:v) ratio in the phosphate buffer solution before injection. A 
Chromaster HPLC (VWR Hitachi) was used. The SE-HPLC was performed on an 
analytical column Shodex Protein KW- 802.5 (8 mm x 300 mm). A 100 mM phosphate 
buffer + NaCl 0.3 M was run isocratically with a flow rate of 0.5 mL.min -1. The column 
oven and autosampler temperatures were kept at 25ºC and at 10ºC, respectively. The 
injection volume was 25 µL. The wavelength was set at 280 nm using a DAD detector. 
The obtained chromatograms were treated and analyzed using the OriginPro8 software.   
 
3.3. Results and discussion   
3.3.1. Concentration factors of PSA 
To optimize the procedure, several ABS without PSA were prepared at different 
compositions along the same TLL (Figure 3.1.) in order to reduce the IL-rich phase and 
to attain the required CF.  
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Figure 3.1. Different compositions along the same TL obtained by applying the lever-arm rule 
which allow to obtain different CF for the ABS composed of K3C6H5O7 + [P4444][CHES] + water. 
 With the exception of [P4444][Tricine], concentration factors up to 250-fold were 
achieved for all the IL-based ABS investigated  (Table 3.1). The representation of each 
system with the corresponding TLs and real CF are depicted in Appendix C. 
[P4444][Tricine] is the most hydrophilic GB-IL used in this work and, as shown in Chapter 
2.3.2., the respective phase diagram is the farthest from the axis. Consequently, it has a 
smaller biphasic region and the theoretical information provided by the lever-arm rule is 
only valid up to concentration factors of 150-fold (Appendix C). 
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Table 3.1. Concentration factors (initial compositions of the mixtures in Appendix C) in the ABS 
composed of [P4444][GB] + K3C6H5O7 + water. ✓: achieved CF; ✕: not achieved CF. 
CF [P4444][CHES] [P4444][MES] [P4444][TES] [P4444][HEPES] [P4444][Tricine] 
5 ✓  ✓ ✓ ✓ ✓ 
20 ✓ ✓ ✓ ✓ ✓ 
50 ✓ ✓ ✓ ✓ ✓ 
100 ✓ ✓ ✓ ✓ ✓ 
150 ✓ ✓ ✓ ✓ ✓ 
200 ✓ ✓ ✓ ✓ ✕ 
250 ✓ ✓ ✓ ✓ ✕ 
 
 After validating the CF achievable with each system, the procedure was then 
repeated by adding an aqueous solution of PSA (at 150 ng/mL) for the mixtures able to 
lead to a CF of 250. These mixture compositions allow to reduce the volume of the IL-
rich phase down to a minimum capable of concentrate PSA in a factor of interest while 
allowing its detection and quantification by SE-HPLC. 
 As observed in the control experiments, CF of 250-fold were also achieved in the 
presence of PSA for all ABS, except for that composed by [P4444][Tricine] (Appendix C). 
The CF were confirmed by weighting both the IL-rich phase and the aqueous solutions 
containing PSA and by the application of Eq. (8). 
Table 3.2. Concentration factor of 250-fold achieved for PSA at the IL-rich phase for the 
systems composed of GB-IL + K3C6H5O7+ PSA. ✓: achieved CF; ✕: not achieved CF. 
CF [P4444][CHES] [P4444][MES] [P4444][TES] [P4444][HEPES] [P4444][Tricine] 
250 ✓ ✓ ✓ ✓ ✕ 
  
 The obtained data suggest that PSA can be extracted and concentrated in a single-
step up to 250-fold using a large variety of IL-GB ABS. However, in the concentration 
process it should be taking into account the protein stability and possible losses (which 
should be avoided).  
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 Figure 3.2. shows the obtained HPLC spectra for the bottom (left) and the top 
(right) phases of the extractions performed for a CF of 250. For terms of comparison, the 
HPLC spectrum of an aqueous solution of pure PSA is also provided with the PSA peak 
appearing between 16 and 18 minutes under the operational conditions used.  
 
Figure 3.2. HPLC spectra of bottom (left) and top (right) phases for the systems composed of 
GB-IL + K3C6H5O7 + water/PSA. A spectrum of pure PSA in water (C= 50 ng/L) is also provided 
as an insert for terms of comparison. 
 The HPLC peak corresponding to PSA is not seen in the bottom phase of any 
extraction. These results are in agreement with those obtained in Chapter 2.3.3. where 
extraction efficiencies of 100% of PSA to the top phase have been achieved. On the other 
hand, the system composed of [P4444][Tricine] results in no peak of PSA detectable by 
HPLC since the CF of 250-fold was not achieved with this system. In addition, a tendency 
is clearly seen in the HPLC spectra: the peak intensity, and thus, the PSA concentration, 
decreases in the following order: [P4444][CHES] > [P4444][MES] > [P4444][TES] > 
[P4444][HEPES] > [P4444][Tricine]. This trend is in close agreement with the PSA losses 
discussed before and that depend on the hydrophobic character of each IL. It is possible 
to see that the most intense peak corresponds to the more hydrophobic IL, [P4444][CHES], 
with the highest log(Kow) value. 
 
3.4. Conclusions 
 Taking into account the theoretical concentration factors achieved and the results 
obtained via HPLC, PSA can be extracted and concentrated in a single step up to 250-
fold and identified with less expensive equipment. The possibility of creating a kit 
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containing fixed amounts of IL and K3C6H5O7 in order to identify cancer biomarkers as a 
clinical/analytical strategy is closer now. Nevertheless, the reported results were attained 
using aqueous solutions of PSA and urine is a complex matrix where coexisting proteins, 
salts and other metabolites can eventually interfere with the process of extraction and 
concentration of PSA. The next chapter describes the application of the enhanced systems 
for the extraction and concentration of PSA from human urine samples. 
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4. Concentration of PSA 
from human fluids using 
optimized IL-based ABS  
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4.1. Introduction 
 Human body fluids include urine, blood, peritoneal fluid, cerebrospinal fluid 
(CSF), sweat, saliva, among others (145). They are remarkable sources of clinical markers 
and are considered potential tools for clinical diagnosis, stage and grade (145). For 
instance, cerebrospinal lysozyme can be useful in distinguish between bacterial and viral 
meningitis (146), while kappa free light chains and CSF in serum support the diagnosis 
of multiple sclerosis (147). The glycated hemoglobin test in blood is an important tool for 
diabetes diagnosis and also to predict the risk of cardiovascular diseases (148). 
 Human body fluids are also clinically relevant in the oncologic field. Several 
cancer biomarkers have been discovered in the past years in biological fluids (51). They 
are produced by cancer cells or in response to their presence, and are mainly proteins, 
such as alpha-Fetoprotein found in blood and used in the diagnosis of liver cancer (Table 
1.2.). DNA, metabolites or RNA transcripts are also important tumor biomarkers as in the 
case of BCR-ABL fusion gene found in blood or in blood marrow used to monitor the 
status of chronic myeloid leukemia (Table 1.2.). The most acceptable biomarker of CaP 
is the prostate-specific antigen (PSA). PSA is a glycoprotein produced by epithelial cells 
of the prostatic gland and reach urine through prostatic ducts. PSA has a cut-off value ≥ 
4.0 ng/mL in serum or ≥ 150 ng/mL in urine have been defined as abnormal and can 
indicate the presence of CaP (68,70). However, the methods used for the purification and 
quantification of PSA and other cancer biomarkers usually involve immunoassays and 
fluorescence- and electrochemical-based methods, which are expensive and time-
consuming, have low reproducibility, and can lead to false negative results (96). 
 Albeit in this work GB-IL ABS have been tested with promising results leading 
to the single-step extraction and concentration of PSA up to 250-fold, the results were 
obtained with model ABS composed of GB-IL + salt + aqueous solutions of known 
concentrations of PSA. Urine is a complex matrix composed of a wide variety of salts, 
proteins and other metabolites (149). In this chapter, ABS composed of [P4444][CHES] 
(the most promising GB-IL) + salt + real urine were tested to check if the other 
components of urine interfere with the process of extraction and concentration of PSA, 
as well as with its identification and quantification. 
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4.2. Experimental Section 
4.2.1. Chemicals 
 The salt, ILs and water used in this section were described in Chapter 2. PSA used 
is also described in chapter 2. The salts required for the HPLC analyses were described 
in Chapter 3.  
 The material required to perform the SDS-PAGE analysis comprise: 
tris(hydroxymethyl)aminomethane, PA from Pronalab; sodium dodecyl sulfate, SDS (> 
98.5 wt % pure) and glycerol, 99.5 wt % pure, from Sigma-Aldrich; bromophenol blue 
and acid acetic, 99.8 wt % pure, from Merck; dithiothreitol, DTT (99 wt % pure), from 
Acros; and methanol, HPLC grade, from Fisher Scientific. The Amersham ECLGel Box, 
the Amersham ECL Running Buffer (10X), the Amersham ECL Gel 4-20 %, 10 wells, 
and the Full-Range Rainbow Molecular Weight Marker were acquired from GE 
Healthcare. The Coomassie Brilliant Blue G-250 was purchased from Sigma-Aldrich. 
 Urine was obtained from random healthy patients. The used urine was the first 
urine of the day. 
 4.2.2. Experimental procedure 
4.2.2.1. Size-exclusion HPLC (SE-HPLC) 
For the preparation of ABS with real urine, PSA (at 150 ng/mL) was firstly added 
to urine before its mixture with the salt and IL. Each mixture was vigorously stirred, 
centrifuged for 10 min, and left to equilibrate for 10 min at (25 ± 1) °C to reach the PSA 
complete partitioning between the coexisting phases. The Falcon tubes used were than 
centrifuged for 10 min at 5000 rpm at (25 ± 1) ºC. After a careful separation of the phases, 
both of them were analyzed by SE-HPLC. An aqueous solution of PSA (0.5 g/L) and pure 
urine were also analyzed. A phosphate buffer solution (1000 mL) was prepared using 47 
mL of a Solution A (27.8g NaH2PO4), 203 mL of a Solution B (53.65g Na2HPO4∙7H2O) 
and 35g of NaCl. Each phase was diluted at a 1:9 (v:v) ratio in the phosphate buffer 
solution before injection. The HPLC conditions used in this step were described in 
Chapter 3. 
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4.2.2.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
The protein profile of urine was determined by SDS-PAGE. The urine samples were 
diluted in the order of 1:1 (v:v) in a dissociation sample buffer constituted by: 2.5 mL of 
0.5 M Tris-HCl pH 6.8, 4.0 mL of 10 % (w:v) SDS solution, 2.0 mL of glycerol, 2.0 mg 
of bromophenol blue and 310 mg of dithiothreitol (DTT). This overall solution was heated 
at 95 ºC for 5 min to reduce the disulphide linkages and to denature the proteins. This 
step allows to overcome some forms of the tertiary protein folding and to break up the 
quaternary proteins structure. Electrophoresis was run on polyacrylamide gels (stacking: 
4 % and resolving: 20 %) with a running buffer consisting in 250 mM TrisHCl, 1.92 M 
glycine, 1 % SDS. The gels were stained with a solution of Coomassie Brilliant Blue G-
250 0.1 % (w:v), methanol 50 % (v:v), acetic acid 7 % (v:v) and water 42.9 % (v:v), in 
an orbital shaker at a moderate speed overnight at room temperature. The distaining of 
the gel was done using a solution containing acetic acid 7 % (v:v), methanol 20 % (v:v) 
and water 73 % (v:v) in an orbital shaker at a moderate speed until remove all the excess 
of dye. SDS-PAGE Molecular Weight Standards, Marker molecular weight full-range 
(VWR), were used as protein standards.  
4.3. Results and discussion 
4.3.1. Concentration of PSA from human urine samples 
 In the previous chapter, it has been demonstrated that PSA can be concentrated up 
to 250-fold in ABS composed of [P4444][CHES], [P4444][MES], [P4444][HEPES] and 
[P4444][TES] + salt + aqueous solution containing PSA at a concentration of 150 ng/mL. 
However, HPLC analyses of the IL-rich phase revealed a tendency for obtaining higher 
peaks with the ABS composed of more hydrophobic GB-ILs, meaning less losses of 
protein. Taking into account these results, [P4444][CHES], the most promising GB-IL 
used, was selected to be tested in the extraction and concentration (CF = 250) of PSA 
from human urine samples.  
 Figure 4.1 represents the macroscopic appearance of the extraction performed 
with [P4444][CHES] + salt + human urine (150 ng/mL of PSA added). The left side of the 
figure shows the ABS after being vigorously stirred, while the right side represents the 
same ABS after being centrifuged for 10 mins (5000 rpm) and being left in equilibrium 
for 15 minutes at 25º C (± 1º C). It is possible to see the formation of a low volume IL-
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rich phase in the top of the ABS (the phase in which PSA is concentrated) and a high 
volume salt rich-phase in the bottom. 
 
Figure 4.1. ABS composed of [P4444][CHES] + salt + human urine (150 ng/mL of PSA added). 
ABS after being vigorously stirred (on the left) and after being centrifuged for 10 min and left in 
equilibrium for 15 min (on the right). 
 By the weighting of the two phases it was observed an increase in the CF, from 
250 to 260, in the presence of urine and when compared with the model systems 
previously investigated. This trend is somehow expected since urine is a more complex 
matrix rich in other salts that result in stronger salting-out phenomenon. Even so, higher 
concentration factors are preferable since they will allow an improved detection and 
quantification of PSA. 
 The top and the bottom phases were analyzed by SE-HPLC, together with a 
sample of pure PSA and human urine for terms of comparison. Figure 4.2. depicts the 
SE-HPLC profile of pure PSA in water, in human urine and in the top and bottom phases 
of an extraction performed with [P4444][CHES] + salt + human urine. 
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Figure 4.2. SE-HPLC profile of pure PSA in aqueous solution, human urine and in the top and 
bottom phases of an ABS composed of [P4444][CHES] + salt + human urine (150 ng/mL of PSA 
added). 
 The peak of PSA in aqueous solution appearing between 16 and 18 minutes is 
clearly seen. This peak is also seen in the top phase of the [P4444][CHES]-based ABS and 
is not found in urine and in the bottom phase of the [P4444][CHES]-based ABS. Therefore, 
PSA has been extracted to the GB-IL-rich phase and concentrated up to a factor that 
allows it to be analyzed by a less expensive and less laborious equipment, such as SE-
HPLC. Even so, the HPLC profiles reveal that there are two other small peaks between 
12 and 16 minutes. PSA is a glycoprotein that can be found in several isoforms with small 
differences of molecular weight. A previous study already revealed a similar profile of 
PSA by SE-HPLC where this small band is identified as bPSA (85). In the top phase of 
the ABS, these peaks have however a higher intensity than the initial aqueous solution of 
PSA, meaning that PSA isoforms were also concentrated by the system composed of GB-
ILs. On the other hand, some of the contaminant metabolites of urine are extracted for the 
opposite phase of the investigated ABS, “cleaning” therefore the phase in which PSA is 
concentrated. Both trends can be seen as a window of opportunity to create an even more 
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accurate PSA test because the PSA isoforms are useful in CaP differential diagnosis (to 
distinguish between CaP and BPH and to predict the cancer aggressiveness)  (5,84,85). 
 In the urine sample, there are a series of other metabolites (with retention times 
between 11 and 12 min) that further appear in the bottom and top phases of the 
investigated ABS. Figure 4.3 - C. depicts the SDS-PAGE of urine where it possible to see 
a band near 45 kDa. This band is possibly associated to alpha-1-antytripsin, a protease 
inhibitor that protect tissues from enzymes of inflammatory cells (150). 
 
Figure 4.3. SDS-PAGE analyses. A: Molecular Wweight marker; B: Pure human serum; C: Pure 
human urine. 
 It is also possible to see two less intense bands between possible alpha-1-
antytripsin and 25 kDa. Thus, these two bands can correspond to proteins or other 
metabolites between this molecular weight, such as apoprotein A1 or apha 1 
microglobulin that usually appears between this range (150). However, it is just a 
prediction and more investigation has to be done to clarify these results, using for instance 
mass spectrometry. 
 4.4. Conclusions 
 The objective of this MSc thesis was achieved since a CF of 250-fold of PSA from 
human urine was achieved allowing its quantification by HPLC. It is possible to believe 
now that a new test for the CaP early detection is closer. However, much more 
A B C
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experiments have to be conducted in order to identify the urine contaminants and whether 
they are interfering with the protein mass balance. Moreover, these analyses should be 
combined with urine samples of a large range of healthy volunteers and CaP patients to 
see if exists a growing trend in the peak intensity according to the disease status.  
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5. Final remarks and 
future work 
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The results obatined in this work lead us to foresee a possible revolution in the 
early-stage detection of CaP. The gathered data show that it is possible to completely 
extract PSA to the IL-rich phase, in a single step, and to concentrate it up to 250-fold from 
urine samples. This work also shows that PSA can be identified and quantified by SE-
HPLC, meaning that urine (non-invasive sampling) can be used in the future for CaP 
diagnosis using less laborious and less expensive equipment, although much more work 
is still needed to correlate the PSA levels in urine and the probability of CaP occurence. 
In this work, a calibration curve for PSA by SE-HPLC is still in need and should be 
performed in the near future in order to test the quantitative approach. It is also from 
crucial importance to analyze a broad number of urine samples from healthy volunteers 
and CaP patients in different stages of the disease to validate the hypothesis that our test 
is useful for CaP early detection. We also believe that it is possible to increase the 
sensibility of our test for the selective and concomitant extraction of PSA and prostatic 
acid phosphatase (an additional CaP biomarker). In summary, much more investigation 
is still required, but the promising preliminary results obtained lead us to believe that in 
a short/medium period it will be possible to develop a new KIT for CaP early-stage 
detection. 
A market-study was finally conducted aiming at our possible competitors in the 
market. In fact, 4 possible competitors have been identified: (i) an academic study being 
carried out by Dr. Goreti Sales, from University of Porto, Portugal, that is developing a 
biosensor for detecting some types of cancer in a cheap, painless and quick way; (ii) the 
PRIMA® company which introduced in the market a simple sensor which uses a drop of 
blood performing an immunoassay (151). Nevertheless, this test has led to a large level 
of reported false positive results; (iii) the Craig Medical Distributions Inc. which offered 
a semi-quantitive immunoassay to be carried out at the patient’s homes. This advantage 
can also be seen as a disadvantageous factor because once the test is performed at the 
patient’s home, some limitations in what concerns sample loss, contamination and 
preservation can be addressed (152). In addition, a unit of this test costs more than 40 €.  
In summary, our biggest competitor is the PSA blood test from PRIMA®. This is 
the most used test for CaP early detection due to its high accuracy and reliability. 
However, it is a time consuming test that requires sample blood collection and specific 
and highly expensive equipment (specific antibodies and immunoassays). In Portugal, a 
PSA blood test costs approximately 20.91 €. Competitively, our test will costs 
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approximately 2.92 €. Moreover, we are proposing the use of urine samples instead of 
blood, representing also a non-invasive approach. Finally, we suggest the use of HPLC 
for PSA quantification instead of immunoassays allowing the broadening of this 
technique to a larger number of clinical laboratories. 
In Portugal, there are no available statistics for the number of PSA blood tests 
performed per year. However, based on an estimation suggested by Dr. Pereira B., an 
urologist from Centro Hospitalar Cova da Beira, Portugal, the 50-75 years old male 
population in Portugal do a PSA analysis in each year. There are 1440,351 males in 
Portugal with that age range (153). In this context, the substitution of the current PSA 
blood test by our approach would result in a money saving of 25 M€ (only in Portugal). 
If we apply this type of calculation to a largest country, such as USA, where more than 
25 million tests are done per year (154), there will be a reduction of 450 M€ associated 
to the PSA screening per year. Those are huge amounts of money that can be used by the 
National Health Associations to provide better conditions to their patients or even, in a 
large term and optimized perspective, to be invested in cancer research.  
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Appendix A 
BLItz® Pro system calibration curve 
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A.1. BLItz Pro® system calibration curve for PSA 
  
 
 
Figure A.1. Calibration curve for PSA in aqueous solution. 
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B.1. Experimental Binodal Data for the Systems Composed of IL + salt + H2O.  
 Table B.1.4. Experimental weight fraction data for the binodal curve of the systems 
composed of [P4444][GB] (1) + K3C6H5O7 (2) at (25 ± 1) °C 
[P4444][TES] 
Mw = 487.69 g.mol-1 
[P4444][MES] 
Mw = 453.66 g.mol-1 
[P4444][HEPES] 
Mw = 496.72 g.mol-1 
100 w1 100 w2 100 w1 100 w2 100w1 100 w2 
76.7069 
70.8659 
68.2725 
65.1872 
61.7348 
59.3491 
57.4007 
55.1249 
51.1784 
48.0776 
45.4535 
44.3554 
43.2974 
41.4746 
39.3799 
37.7142 
36.7566 
35.7102 
34.4566 
33.1800 
32.2965 
31.3356 
30.8074 
29.8842 
29.4592 
28.6566 
27.9593 
27.2225 
0.9602 
1.3572 
2.1660 
2.4366 
2.9165 
3.8172 
4.3772 
4.6711 
5.6150 
6.7585 
7.5826 
8.0084 
8.3144 
9.2730 
10.1176 
10.7034 
11.0932 
11.6940 
12.4919 
12.8464 
13.2737 
13.8476 
13.9839 
14.5095 
14.5563 
14.9631 
15.3925 
15.8238 
62.3717 
55.0746 
46.1457 
38.9888 
35.5324 
32.1736 
29.2351 
25.0058 
24.3730 
23.4465 
22.7324 
22.1010 
21.0463 
20.1913 
19.8753 
19.2960 
18.8178 
18.4771 
17.9601 
17.5589 
17.1589 
16.7271 
16.3047 
15.9311 
15.7730 
15.0549 
14.7790 
14.4682 
1.9534 
3.0687 
5.2053 
7.5466 
9.4461 
10.4337 
12.1770 
14.2196 
14.9448 
15.5913 
15.9857 
16.2701 
17.2067 
17.4856 
17.7077 
18.0770 
18.3213 
18.7802 
19.0542 
19.3400 
19.5134 
19.9010 
20.0070 
20.2144 
20.5767 
21.1613 
21.3413 
21.4879 
79.0463 
57.3815 
54.3893 
52.9863 
51.0045 
49.7780 
48.5506 
46.8489 
45.8407 
44.9174 
43.9395 
43.0836 
42.2405 
41.0589 
40.2864 
39.6085 
38.7789 
38.0856 
37.1480 
36.5145 
35.9247 
35.0893 
34.5783 
33.9887 
33.2017 
32.7173 
31.9773 
31.5401 
1.2140 
3.8233 
4.3607 
4.8784 
5.2142 
5.7866 
6.4546 
6.7966 
7.2063 
7.5423 
8.0321 
8.3337 
8.6264 
9.4620 
9.7631 
9.9950 
10.4148 
10.7895 
11.5128 
11.8715 
12.1013 
12.6849 
12.8815 
13.0928 
13.6317 
13.8141 
14.3907 
14.5988 
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26.4220 
25.5657 
24.2081 
23.8472 
23.2970 
22.9946 
22.3836 
21.6036 
21.3292 
20.8961 
20.4677 
20.2223 
19.7738 
19.2462 
18.9256 
18.6499 
18.2835 
17.6456 
17.4407 
17.1177 
16.9670 
16.5536 
16.1634 
15.9537 
15.7829 
15.5580 
15.1395 
14.9734 
14.6763 
14.3540 
14.2098 
14.0587 
13.8147 
13.4649 
13.3046 
15.9225 
16.3281 
16.8379 
16.9281 
17.3304 
17.3495 
17.7987 
18.2128 
18.2571 
18.5831 
18.8857 
18.8879 
19.1910 
19.3739 
19.5577 
19.7752 
20.0163 
20.3441 
20.3563 
20.6181 
20.7616 
21.1438 
21.2496 
21.3318 
21.3693 
21.3169 
21.5924 
21.6647 
21.9494 
22.0933 
22.1238 
22.1748 
22.4282 
22.6969 
22.7489 
14.0210 
13.5973 
13.3496 
13.1172 
12.8557 
12.6174 
12.3314 
12.1281 
11.9372 
11.6437 
11.4069 
11.1862 
10.8123 
106356 
10.2575 
10.0548 
9.9013 
9.7624 
9.4916 
9.3455 
 
21.8603 
22.2147 
22.4360 
22.5457 
22.7482 
22.8941 
23.0981 
23.2549 
23.4139 
23.7911 
23.8702 
24.1448 
24.4067 
24.5665 
25.3191 
25.3267 
25.4396 
25.5814 
25.9226 
26.1029 
 
31.0895 
30.4952 
30.0682 
29.4377 
29.0323 
28.4782 
28.1064 
27.5444 
27.1562 
26.7717 
26.2562 
25.9124 
25.5547 
25.0862 
24.7562 
24.4325 
24.1295 
23.8514 
23.5605 
23.1424 
22.8762 
22.5964 
22.3685 
22.0924 
21.7425 
21.4919 
21.2324 
20.9928 
20.7564 
20.5049 
20.1739 
19.9540 
19.7418 
19.5269 
19.3328 
14.7894 
15.2897 
15.4687 
15.9744 
16.1842 
16.6043 
16.7660 
17.2465 
17.4312 
17.6314 
18.0963 
18.2348 
18.4400 
18.8429 
19.0434 
19.1928 
19.3462 
19.4689 
19.6638 
20.0931 
20.2151 
20.4074 
20.5117 
20.6744 
21.0080 
21.1585 
21.3295 
21.5054 
21.6458 
21.8034 
22.1712 
22.3240 
22.4395 
22.5751 
22.6994 
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13.0039 
12.8723 
12.6612 
12.3640 
12.1186 
11.8639 
11.6571 
11.4390 
11.1471 
10.9409 
10.6828 
10.4964 
10.2787 
9.9800 
 
23.1101 
23.1770 
23.3747 
23.5577 
23.6864 
23.8066 
23.9221 
24.0440 
24.3031 
24.3849 
24.5823 
24.6401 
24.7997 
25.0353 
 
 
19.1294 
18.9272 
18.7374 
18.5586 
18.3699 
18.1792 
17.9884 
17.8004 
17.6390 
17.4725 
17.3051 
17.0633 
16.9135 
16.7573 
16.6179 
16.4627 
16.3114 
16.1609 
16.0083 
15.8933 
15.7494 
15.6078 
15.4442 
15.2482 
14.9644 
14.7844 
14.6638 
14.5404 
14.4274 
14.3273 
14.2180 
14.1053 
14.0054 
13.9034 
13.6752 
22.8101 
22.9416 
23.0451 
23.1337 
23.2760 
23.3980 
23.5619 
23.7110 
23.8141 
23.8990 
23.9930 
24.2733 
24.3400 
24.4280 
24.4931 
24.5548 
24.6708 
24.8339 
24.9827 
25.0836 
25.1729 
25.2723 
25.3540 
25.4261 
25.5705 
25.5726 
25.6354 
25.7313 
25.7960 
25.8698 
25.9580 
26.0754 
26.1412 
26.2410 
26.4403 
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13.4380 
13.3321 
13.1223 
13.0212 
12.9296 
12.8243 
12.7332 
12.6435 
12.5550 
12.4512 
12.3510 
12.2638 
12.1809 
12.0351 
11.9108 
11.8294 
11.7417 
11.6583 
11.5681 
11.4415 
11.3621 
11.2111 
11.1332 
11.0554 
10.9783 
10.9028 
10.8242 
10.7550 
10.6903 
10.5568 
10.4514 
10.3869 
10.3099 
10.1744 
10.1046 
26.5215 
26.6150 
26.9538 
27.0392 
27.0986 
27.1788 
27.2597 
27.3055 
27.3834 
27.4816 
27.5601 
27.6426 
27.7100 
27.5498 
27.5261 
27.6381 
27.7355 
27.7854 
27.7946 
27.9978 
28.0604 
28.1925 
28.2368 
28.3165 
28.3645 
28.4271 
28.4983 
28.5507 
28.5929 
28.6798 
28.8405 
28.8751 
28.9227 
29.0601 
29.1099 
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9.9960 
9.9331 
9.8652 
9.7744 
9.7142 
9.6508 
9.5954 
9.5060 
9.3880 
9.2867 
9.1271 
9.0140 
 
29.2017 
29.2384 
29.2873 
29.4242 
29.4694 
29.5226 
29.5549 
29.7251 
29.7914 
29.8751 
29.8189 
29.8419 
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Table B.1.2 Experimental weight fraction data for the binodal curve of the systems composed 
of [P4444][GB]  (1) + K3C6H5O7 (2) at (25 ± 1) °C. 
[P4444][CHES] 
Mw = 465.71 g.mol-1 
[P4444][Tricine] 
Mw = 437.59 g.mol-1 
100w1 100 w2 100w1 100 w2 
44.7594 
41.7133 
39.3281 
37.5478 
36.2173 
34.4777 
33.4844 
32.3207 
30.9793 
29.7327 
28.7294 
27.9449 
27.3862 
26.6892 
25.8564 
25.2516 
24.5309 
23.9560 
23.3246 
22.7933 
22.4552 
21.9599 
21.4739 
21.0590 
20.5271 
20.0348 
19.6862 
19.2679 
18.9461 
18.5846 
18.2738 
3.9161 
4.7445 
5.3443 
5.8334 
6.3403 
6.6717 
7.0417 
7.4695 
7.8335 
8.1674 
8.3923 
8.7909 
9.1807 
9.5276 
9.6746 
10.0156 
10.2402 
10.6026 
10.7184 
10.8318 
11.1649 
11.2770 
11.4556 
11.7289 
11.9246 
12.0460 
12.2523 
12.3565 
12.5667 
12.6653 
12.8611 
77.5111 
69.0398 
60.3936 
45.3106 
43.2973 
41.7906 
40.7737 
39.4115 
38.4819 
37.5246 
36.6356 
35.8293 
35.0777 
34.3202 
33.6512 
32.9250 
32.2737 
31.5877 
30.9769 
30.4459 
29.8602 
29.3288 
28.7964 
27.9689 
27.5021 
27.0526 
26.6139 
26.1790 
25.5152 
25.1113 
24.7146 
1.3976 
3.2813 
4.6040 
10.9072 
12.0387 
12.7137 
13.4039 
13.8630 
14.5159 
15.0688 
15.6331 
16.1561 
16.6438 
17.1529 
17.6142 
18.0855 
18.5240 
18.9671 
19.3892 
19.6828 
20.0574 
20.4102 
20.7798 
21.6115 
21.9881 
22.2898 
22.5766 
22.8039 
23.4747 
23.7524 
23.9830 
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17.9125 
17.6078 
17.2418 
16.9497 
16.5959 
16.2658 
15.9372 
15.6394 
15.3494 
15.0804 
14.8653 
14.6160 
14.3627 
14.1691 
13.9297 
13.7059 
13.4937 
13.3214 
13.0987 
12.8854 
12.6897 
12.5331 
12.3603 
12.1796 
11.9638 
11.8745 
11.7315 
11.6065 
11.4715 
11.3333 
11.2234 
11.1094 
11.0086 
10.8894 
10.7829 
12.9048 
13.1377 
13.1908 
13.3802 
13.5326 
13.6967 
13.8345 
13.9743 
14.1216 
14.1880 
14.1273 
14.1969 
14.2270 
14.4094 
14.5667 
14.6082 
14.7288 
14.8631 
14.9625 
15.0692 
15.1054 
15.2312 
15.2814 
15.4112 
15.3512 
15.5212 
15.6061 
15.7144 
15.7766 
15.8107 
15.8936 
15.9354 
16.0450 
16.0704 
16.1802 
24.2941 
23.9505 
23.4108 
23.0802 
22.7777 
21.9759 
21.6897 
21.2422 
20.9856 
20.7143 
20.2641 
20.0440 
19.6646 
19.4356 
19.2146 
18.8964 
18.6063 
18.3036 
18.1074 
17.7775 
17.5843 
17.4062 
17.1936 
16.9327 
16.6746 
16.5059 
16.2517 
16.0879 
15.8639 
15.6137 
15.3613 
15.2180 
14.9933 
14.7745 
14.5414 
24.1475 
24.3704 
24.9376 
25.1276 
25.3079 
25.9534 
26.1745 
26.6289 
26.7786 
26.9484 
27.4060 
27.4713 
27.8548 
28.0177 
28.1671 
28.4463 
28.7423 
29.0215 
29.1358 
29.4780 
29.5748 
29.7475 
29.8764 
30.1473 
30.3763 
30.5192 
30.7703 
30.8671 
31.0559 
31.2773 
31.5346 
31.5846 
31.7975 
31.9996 
32.2434 
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10.5886 
10.4981 
10.3988 
10.3033 
10.1787 
10.0473 
9.9031 
9.8062 
9.7334 
9.6460 
9.5454 
9.4609 
9.3665 
9.2806 
9.1653 
9.0362 
8.8758 
 
 
 
 
 
 
 
16.1623 
16.2169 
16.3194 
16.3790 
16.4264 
16.6499 
16.6303 
16.6971 
16.7589 
16.8281 
16.8790 
16.9587 
16.9371 
17.0041 
17.1692 
17.3527 
17.4518 
 
 
 
 
 
 
 
14.2661 
14.0897 
13.9659 
13.7769 
13.6422 
13.4665 
13.2741 
13.0964 
12.8799 
12.7729 
12.4852 
12.0250 
11.8725 
11.7110 
11.5823 
11.4282 
11.3124 
11.1593 
11.0294 
10.8889 
10.8121 
10.7023 
10.4568 
 
 
 
32.4125 
32.6000 
32.6448 
32.8457 
32.9745 
33.1494 
33.2291 
33.4211 
33.7079 
33.7572 
33.9822 
34.0183 
34.1810 
34.3599 
34.4851 
34.6641 
34.7944 
34.8316 
35.0037 
35.1658 
35.1672 
35.3094 
35.5745 
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Experimental data for CF  
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C.1. Experimental data for the concentration factors in ABS composed of IL + salt + 
H2O. 
Table C.1.5. Experimental data for the CF of the systems composed of [P4444][GB] + 
K3C6H5O7 + water at (25 ± 1) °C 
[P4444][MES] 
Theoretical 
CF 
5 20 50 100 150 200 250 
w IL / g 0.1538 0.8746 0.9034 0.4669 0.608 0.3206 0.2578 
w  Salt/ g 0.4907 11.1844 28.8004 29.0330 58.2693 40.8537 40.8927 
w H2O/ g 0.3556 7.9404 20.3765 20.5313 41.1231 28.8267 28.8521 
w Top/ g 0.0783 0.4023 0.4108 0.2064 0.2603 0.1476 0.1166 
w Bottom/ g 0.8099 18.7884 48.9843 46.2209 98.9366 69.2375 69.1359 
Real CF 4.54 19.74 49.60 99.47 157.98 195.30 247.45 
 
[P4444][CHES] 
Theoretical 
CF 
5 20 50 100 150 200 250 
w IL / g 0.1546 0.8718 0.896 0.4543 0.3079 0.317 0.2541 
w  Salt/ g 0.4918 11.2273 28.8647 29.1384 29.2327 40.9848 41.0242 
w H2O/ g 0.3553 7.9012 20.2728 20.4156 20.4793 28.7043 28.7221 
w Top/ g 0.0855 0.4322 0.3842 0.2101 0.1319 0.1406 0.1174 
w Bottom/ g 0.8246 17.8944 48.8542 49.2884 49.1391 68.4552 69.6864 
Real CF 4.16 18.28 52.77 97.17 155.26 204.16 244.65 
 
[P4444][HEPES] 
Theoretical 
CF 
5 20 50 100 150 200 250 
w IL / g 0.1590 0.8554 0.8861 0.4548 0.6189 0.3307 0.2691 
w  Salt/ g 0.4999 11.3395 29.164 29.4442 57.0792 41.4222 41.4620 
w H2O/ g 0.3530 7.8059 19.95 20.1002 40.3018 28.2491 28.273 
w Top/ g 0.0730 0.4038 0.3922 0.2042 0.264 0.142 0.1119 
w Bottom/ g 0.7998 18.8912 48.7235 49.3160 98.9670 68.8742 69.4209 
Real CF 4.84 19.33 50.87 98.43 152.66 198.94 252.66 
 
[P4444][TES] 
Theoretical 
CF 
5 20 50 100 150 200 250 
w IL / g 0.1565 0.6673 0.9148 0.4615 0.3091 0.3267 0.2603 
w  Salt/ g 0.4839 8.2646 28.3289 28.6225 28.7143 40.266 40.3037 
w H2O/ g 0.3588 6.0672 20.7886 20.9159 20.9797 29.413 29.4364 
w Top/ g 0.0801 0.3159 0.4201 0.2118 0.1394 0.1438 0.115 
w Bottom/ g 0.7982 14.2206 48.4881 49.3160 49.1121 67.8044 69.5518 
Real CF 4.48 19.21 49.48 98.75 150.50 204.54 255.97 
 100 
 
[P4444][Tricine] 
Theoretical 
CF 
5 20 50 100 150 200 250 
w IL / g 0.1582 0.9758 1.1577 0.7204 0.5731   
w  Salt/ g 0.4862 11.1054 28.575 28.8193 28.0000   
w H2O/ g 0.3542 7.931 20.3498 20.4447 20.5376   
w Top/ g 0.0800 0.4147 0.4138 0.2111 0.1426   
w Bottom/ g 0.7948 19.4130 49.1102 49.3373 49.3575   
Real CF 4.43 19.12 49.18 96.85 144.02   
 
 
 
 
Figure C.1.6. Experimental data for CF of the systems composed of [P4444][GB] + 
K3C6H5O7 + water at (25 ± 1) °C 
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